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Abstract
Mitochondria	are	highly	integrated	organelles	that	are	crucial	to	cell	adaptation	and	
mitigating	adverse	physiology.	Recent	studies	demonstrate	that	fundamental	signal	
transduction	pathways	incorporate	mitochondrial	substrates	into	their	biological	pro‐
grams.	Reversible	phosphorylation	 is	emerging	as	a	useful	mechanism	to	modulate	
mitochondrial	function	in	accordance	with	cellular	changes.	Critical	serine/threonine	
protein	kinases,	 such	as	 the	c‐Jun	N‐terminal	kinase	 (JNK),	protein	kinase	A	 (PKA),	
PTEN‐induced	kinase‐1	(PINK1),	and	AMP‐dependent	protein	kinase	(AMPK),	readily	
translocate	to	the	outer	mitochondrial	membrane	(OMM),	the	interface	of	mitochon‐
dria‐cell	communication.	OMM	protein	kinases	phosphorylate	diverse	mitochondrial	
substrates	that	have	discrete	effects	on	organelle	dynamics,	protein	import,	respira‐
tory	 complex	 activity,	 antioxidant	 capacity,	 and	 apoptosis.	 OMM	 phosphorylation	
events	can	be	tempered	through	the	actions	of	local	protein	phosphatases,	such	as	
mitogen‐activated	 protein	 kinase	 phosphatase‐1	 (MKP‐1)	 and	 protein	 phosphatase	
2A	(PP2A),	to	regulate	the	extent	and	duration	of	signaling.	The	central	mediators	of	
OMM	signal	transduction	are	the	scaffold	proteins	because	the	relative	abundance	of	
these	accessory	proteins	determines	the	magnitude	and	duration	of	a	signaling	event	
on	the	mitochondrial	surface,	which	dictates	the	biological	outcome	of	a	local	signal	
transduction	pathway.	The	concentrations	of	scaffold	proteins,	such	as	A‐kinase	an‐
choring	proteins	 (AKAPs)	and	Sab	 (or	SH3	binding	protein	5—SH3BP5),	have	been	
shown	 to	 influence	 neuronal	 survival	 and	 vulnerability,	 respectively,	 in	 models	 of	
Parkinson's	disease	(PD),	highlighting	the	importance	of	OMM	signaling	to	health	and	
disease.	 Despite	 recent	 progress,	 much	 remains	 to	 be	 discovered	 concerning	 the	
mechanisms	 of	OMM	signaling.	Nonetheless,	 enhancing	 beneficial	OMM	signaling	
events	and	 inhibiting	detrimental	protein‐protein	 interactions	on	the	mitochondrial	
surface	may	 represent	highly	 selective	approaches	 to	 restore	mitochondrial	health	
and	homeostasis	and	mitigate	organelle	dysfunction	in	conditions	such	as	PD.
K E Y W O R D S
A‐kinase	anchoring	protien,	c‐Jun	N‐terminal	Kinase	(JNK),	leucine‐rich	repeat	kinase	2	
(LRRK2),	PTEN‐induced	kinase‐1	(PINK‐1)	mitochondria,	outer	mitochondrial	membrane,	
protein	phosphatase,	Sab	(SH3‐binding	protein	5;	SH3BP5)
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1  | BACKGROUND
Mitochondria	are	highly	integrated	organelles	responsible	for	reg‐
ulating	cellular	bioenergetics	and	viability	in	a	continually	changing	
environment.	This	extensive	level	of	integration	requires	intricate	
and	precise	 systems	 for	 communication	with	other	 cellular	 com‐
partments.	 As	 the	 cellular	 environment	 changes,	 mitochondria	
must	 adjust	 their	 function,	 and	 cells	must	 be	 able	 to	 detect,	 re‐
spond,	and	modulate	mitochondria	rapidly	to	adapt.	Mitochondria	
have	 evolved	 sophisticated	 signaling	mechanisms	with	 cells	 that	
involve	 gases,	 ions,	 hormones,	 metabolites,	 and	 proteins.1	 Thus,	
mitochondria	are	crucial	hubs	for	receiving,	integrating,	and	trans‐
mitting	signals	within	cells.2	Environmental,	cellular,	and	organelle‐
based	 messengers	 impact	 all	 areas	 of	 mitochondrial	 physiology	
including	genome	integrity,	bioenergetics,	translation,	and	protein	
import	(Figure	1).3
The	quickness	necessitated	 for	 accurately	 adjusting	mitochon‐
drial	function	to	physiological	perturbations	implies	that	post‐trans‐
lational	modifications	 (PTMs)	of	 local	proteins	are	used	before	the	
induction	 of	 transcriptional	 programs.	 Reversible	 phosphorylation	
has	emerged	as	 a	prominent	mechanism	 for	 rapidly	 regulating	mi‐
tochondrial	 protein	 function;	 in	 fact,	 recent	 proteomic	 studies	 in‐
dicate	 that	~40%	of	 the	organelle	 proteome	 is	 phosphorylated.4‐8 
Additionally,	over	30	protein	kinases	and	phosphatases	are	reported	
to	migrate	 to	mitochondria	 or	 have	mitochondrial	 substrates.6,8‐11 
These	 phosphorylation	 events	 affect	 metabolism,	 mitochondrial	
dynamics,	organelle	function,	and	apoptosis	demonstrating	the	im‐
portance	of	coordinated	mitochondria‐cell	communication.
The	outer	mitochondrial	membrane	(OMM)	is	the	interface	be‐
tween	mitochondria	and	the	rest	of	the	cell.	Despite	that	most	mito‐
chondrial	proteins	reside	within	the	inner	mitochondrial	membrane	
(IMM),	the	OMM	hosts	significant	elements	of	mitochondrial	phys‐
iology	including	organelle	dynamics,	protein	import,	and	apoptosis.	
Consequently,	protein	kinases	and	phosphatases	on	the	OMM	are	
appropriately	 positioned	 to	 convey	 signals	 to	 and	 from	mitochon‐
dria	 to	 directly	 manipulate	 mitochondrial	 form	 and	 function.	 The	
importance	 of	 OMM	 signaling	 is	 supported	 by	 numerous	 studies	
demonstrating	 that	 cytosolic	 kinases	migrate	 to	 the	organelle	 sur‐
face	 and	 modify	 local	 substrates	 to	 affect	 mitochondrial	 physiol‐
ogy.8,9,11	 Neurons	 have	 a	 particular	 reliance	 on	 mitochondria	 for	
energy	production,	calcium	buffering,	and	managing	 ionic	changes	
related	 to	 synaptic	 transmission.12	 Furthermore,	 dysfunction	 of	
OMM	signaling	components	can	contribute	to	the	pathophysiology	
of	neurodegenerative	diseases,	such	as	Alzheimer's	disease	(AD)	and	
Parkinson's	disease	(PD).9,13
In	this	review,	we	will	identify	the	kinases	and	phosphatases	found	
on	the	OMM	(summarized	in	Table	1)	of	neurons	and	other	CNS	cells.	
We	will	present	the	molecular	architecture	required	for	each	signaling	
protein	and	discuss	the	effects	of	specific	substrate	phosphorylation	
events	 including	 the	 impacts	 on	 organelle	 and	 neuronal	 physiology.	
We	will	highlight	how	perturbations	in	kinase	and	phosphatase	activ‐
ities	can	contribute	to	the	pathophysiology	of	neurological	diseases.
F I G U R E  1  Mitochondrial	signaling	mechanisms	regulate	organelle,	cell,	and	organisms	physiology.	Mitochondria	are	influenced	by	the	
intracellular	and	extracellular	stimuli	such	as	ions,	metabolites,	and	molecules	in	the	environment	like	oxygen	and	pesticides.	However,	the	
impact	of	signaling	cascades	in	response	to	indirect	actions	of	second	messengers	or	stressors	is	emerging	as	significant	manipulators	of	
physiology.	Mitochondrial	signaling	and	second	messengers	have	been	shown	to	affect	mitochondrial	processes	ranging	from	local	events	
such	as	bioenergetics,	mitochondrial	dynamics,	and	proteins	import	to	controlling	transcriptional	programs	such	as	mitochondrial	biogenesis,	
gene	expression,	and	redox	homeostasis.	Of	course,	mitochondria	are	crucial	to	cell	viability	because	the	organelles	are	home	to	cell	death	
machinery.	Mitochondrial	signaling	can	also	transcend	the	cell	through	metabolites,	second	messengers,	and	even	extracellular	vesicles	to	
impact	metabolism,	immune	responses,	inter‐tissue	signaling,	and	the	microbiota	within	an	organism.	Mitochondrial	signaling	has	emerged	
as	a	critical	component	to	human	health	and	disease.	The	stimuli	and	transcriptional	programs	converge	on	signaling	proteins	on	the	outer	
mitochondrial	membrane	(OMM),	which	are	uniquely	positioned	to	receive	and	convey	signals	from	both	cell	and	organelle.	Discrete	OMM	
signaling	events	then	coordinate	mitochondrial	and	cellular	responses	to	adapt	organelle,	cell,	and	organismal	physiology	to	the	current	
environment
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TA B L E  1  Summary	of	select	mitochondrial	substrates	of	OMM	kinases	and	phosphatases
Protein
Proposed 
substrates Amino acid Inhibit/activate Pathway/activity
Suppress/
promote Identified on OMM Ref.
Kinase        
AMPK MFF
AKAP‐1
Ser172
Ser103
Activate
Activate
Fission
Signaling
Promote
Promote
Colocalization
Phosphoproteomics
266
120
Cdk1 Drp‐1 Ser616 Activate Fission Promote Colocalization 195
Cdk5 Drp‐1 Ser616 Activate Fission Promote Colocalization  
Cdk11 Unknown   Apoptosis  Colocalization 203
CKI Bid Ser64/66 Inhibit Apoptosis Suppress Colocalization 207
CK2 Bcl‐2	proteins
FUNDC1
MIM1/2
TOM20
TOM22
Ser13
Ser12/16
Ser172
Ser44/46
Inhibit
Inhibit
Inhibit
Inhibit
Inhibit
Apoptosis
Mitophagy
Protein	import
Protein	import
Protein	import
Suppress
Suppress
Suppress
Suppress
Suppress
Colocalization 207
210
123
ERK1/2 Bcl‐2	proteins
Drp‐1
Mfn1
PGK‐1
StAR
TRAP1
Ser616
Thr562
Ser203
Ser232
Ser511/568
Inh/Act
Activate
Inhibit
Activate
Activate
Activate
Apoptosis
Fission
Fusion
Metabolism
Metabolism
Metabolism
Supp/Prom
Promote
Suppress
Suppress
Promote
Suppress
Colocalization 62
75
76
77
80
78
JNK Bcl‐2	proteins
Mfn2
PDH‐Eα1
SH3BP5
Smac/DIABLO
smARF2
Ser27
TBD
Ser421
Ser6
TBD
Inh/Act
Inhibit
Inhibit
Activate
Activate
Activate
Apoptosis
Fusion
Metabolism
Signaling
Apoptosis
Mitophagy
Supp/Prom
Suppress
Suppress
Promote
Promote
Promote
Colocalization 34
57
52,53
28
47
56
LRRK2 Bcl‐2
Miro
MCU
PRDX3
Thr56
TBD
TBD
Thr146
Activate
Inhibit
Activate
Inhibit
Autophagy
Trafficking
Ca2+	Transit
Antioxidant
Promote
Suppress
Promote
Suppress
Colocalization 159
164
165
166
mTOR Bcl‐xL Ser62 Activate Glycolysis Promote Colocalization 216
PAK5 Bad Ser112 Inhibit Survival Suppress Colocalization 223
PINK1 AKAP‐1
Parkin
PINK1
Ub
TBD
Ser65
Ser228/402
Ser65
Inhibit
Activate
Activate
Activate
Signaling
Mitophagy
Mitophagy
Mitophagy
Suppress
Promote
Promote
Promote
Colocalization
Proteomics
178
179
173
175
PKA AIF1
Bad
Bax
Bim
Drp1
GSTA4‐4
MIC19
MIC60
NDUFS4
TOM22
TOM40
TOM70
VDAC1
Ser39
Ser112/155
Ser60
Ser83
Ser637
Ser189
Thr11
Ser528
Ser173
Thr76
Ser54
Ser174
TBD
Inhibit
Inhibit
Inhibit
Inhibit
Inhibit
Activate
Inhibit
Inhibit
Activate
Inhibit
Inhibit
Inhibit
Inhibit
Bioenergetics
Apoptosis
Apoptosis
Apoptosis
Fission
Antioxidant
MICOS/Mitophagy
MICOS/Mitophagy
Bioenergetics
Protein	Import
Protein	Import
Protein	Import
Ion	Homeostasis
Promote
Suppress
Suppress
Suppress
Suppress
Promote
Suppress
Suppress
Promote
Suppress
Suppress
Suppress
Suppress
Colocalization
Proteomics
131
95
129
130
121
105
105
110
124
125
126
267
PKC Drp‐1
ECE‐1
Ser616
TBD
Activate
Activate
Fission
Amyloid	Clearance
Promote
Promote
Colocalization 149
152
P38γ Bcl‐2	proteins
Sab	(SH3BP5)
TBD Inh/Act
Activate
Apoptosis
Signaling
Supp/Prom
Promote
Colocalization 81
86
(Continues)
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2  | OMM PROTEIN KINASES
Protein	 kinases	 influence	 mitochondrial	 protein	 function	 through	
phosphorylation.	 Intriguingly,	 most	 kinase	 activity	 within	 mito‐
chondria	 can	 be	 attributed	 to	 tyrosine	 kinases	 such	 as	 Src.14,15 
Alternatively,	 much	 of	 the	 phosphorylation	 on	 the	 mitochondrial	
surface	 is	 associated	 with	 serine/threonine	 (Ser/Thr)	 protein	 ki‐
nases.8	Accordingly,	the	OMM	protein	kinases	are	almost	exclusively	
Ser/Thr	kinases,	which	we	will	discuss	below.
3  | MITOGEN‐ACTIVATED PROTEIN 
KINASES (MAPKS)
MAPKs,	namely	the	c‐Jun	N‐terminal	kinase	(JNK),	extracellular	regu‐
lated	kinase	(ERK1/2),	and	p38,16	exhibit	transient	mitochondrial	locali‐
zation	in	responses	to	cellular	stimuli	and	stress.	The	principal	targets	
of	mitochondrial	MAPKs	appear	 to	be	the	Bcl‐2	protein	superfamily	
members,	which	explains	 the	 impact	mitochondrial	MAPKs	have	on	
the	regulation	of	cell	death	pathways.16	Recent	studies	show	that	JNK,	
ERK,	and	p38	can	phosphorylate	OMM	substrates	 involved	 in	mito‐
chondrial	dynamics	and	bioenergetics.
3.1 | c‐Jun N‐terminal kinase
The	 most	 well‐characterized	 MAPK	 with	 OMM	 localization	 is	
the	c‐Jun	N‐terminal	kinase	 (JNK).	There	are	three	JNK	 isoforms	
(JNK1,	JNK2,	and	JNK3)	that	are	expressed	in	the	brain,	and	stud‐
ies	from	mice	suggest	that	JNK	isoforms	account	for	most	of	the	
proline‐directed	phosphorylation	in	the	brain.17,18	The	activities	of	
JNKs	have	been	delineated	 in	 rodent	brains	with	JNK1	account‐
ing	 for	 most	 of	 the	 signaling	 in	 the	 cortex	 and	 cerebellum,	 and	
JNK3	 accounts	 for	 the	 bulk	 of	 activity	 in	 the	 hippocampus	 and	
striatum.19,20	 Discrete	 subcellular	 may	 contribute	 to	 the	 diverse	
JNK	 substrates	 and	 physiological	 roles	 of	 JNK	 signaling	 in	 the	
brain	with	nuclear	and	cytosolic	isoforms	targeting	different	sub‐
strate	pools.	The	cytosolic	JNK	species	probably	become	the	mi‐
tochondrial	JNK	species	based	on	localization.	Also,	the	functional	
redundancy	and	compensatory	activities	of	JNK	isoforms	indicate	
that	multiple	JNKs	could	contribute	to	mitochondrial	JNK	signal‐
ing.18,21,22	 In	 cerebral	 ischemia,	 researchers	 propose	 that	 JNK1	
may	be	an	early	mitochondrial	effector	with	JNK3	migrating	to	mi‐
tochondria	later	and	inducing	apoptosis.23	Similarly,	in	1‐methyl‐4‐
phenyl‐1,2,3,6‐tetrahydropyridine	 (MPTP)‐induced	 dopaminergic	
(DA)	 neuron	 degeneration	 in	 mice,	 ablation	 of	 both	 JNK2	 and	
JNK3	was	necessary	to	protect	DA	neurons	from	the	neurotoxic	
insult.24,25	These	data	imply	that	JNK1	is	involved	in	physiological	
JNK	signaling,	while	JNK2	and	JNK3	are	responsible	for	JNK‐me‐
diated	apoptosis;	meanwhile,	these	studies	highlight	the	potential	
for	all	JNK	isoforms	to	localize	on	mitochondria.
Mitochondrial	JNK	signaling	is	 linked	to	apoptosis	 in	numerous	
tissues,	 including	 the	 brain,	 following	 cytotoxic	 stress.	While	 the	
molecular	mechanism	of	JNK	translocation	to	the	OMM	remains	to	
be	determined,	the	scaffold	protein,	Sab	(or	SH3BP5),	anchors	JNK	
on	mitochondria.26‐28	 Sab	 is	 a	 single‐pass	 transmembrane	 protein	
oriented	in	the	OMM	with	the	N	terminus	of	the	protein	in	the	mito‐
chondrial	intermembrane	space	and	the	C	terminus	on	the	cytosolic	
face	of	the	OMM.29	JNK	interacts	with	Sab	through	kinase	interact‐
ing	motifs	(KIM1/2)	near	the	C	terminus	of	Sab,26,28,30	and	ablation	
of	these	sites	or	use	of	a	competitive	peptide	(Tat‐SabKIM1)	can	pre‐
vent	JNK	translocation	to	mitochondria.26,31,32	Disrupting	the	inter‐
action	between	JNK	and	Sab	is	neuroprotective	in	rodent	models	of	
PD	and	cerebral	ischemia.23,33
Mitochondrial	JNK	activity	impacts	apoptosis,	metabolism,	and	
organelle	dynamics	 (Figure	2);	perhaps,	 the	most	widely	 identified	
JNK	mitochondrial	substrates	are	proteins	from	the	Bcl‐2	superfam‐
ily.34	JNK	phosphorylates	many	members	of	 the	Bcl‐2	superfamily	
to	 modulate	 their	 functions	 in	 stress,	 tissue,	 and	 cell‐dependent	
Protein
Proposed 
substrates Amino acid Inhibit/activate Pathway/activity
Suppress/
promote Identified on OMM Ref.
Phosphatase        
MKP‐1 JNK
MAPKs
Thr183/
Tyr185
Inhibit
Inhibit
Apoptosis
ROS	production
Suppress
Suppress
Colocalization 224
PP1 AKAP1
Bad
Bcl‐2
P38
TBD
Ser112/136
Ser70
Thr180/
Tyr182
Activate
Activate
Inhibit
Inhibit
Signaling
Apoptosis
Apoptosis
Signaling
Promote
Promote
Suppress
Suppress
Colocalization 248
236
230
231
PP2A Bad
Bcl‐2
Drp1
Ser112
Ser70
Ser656
Activate
Inhibit
Activate
Apoptosis
Apoptosis
Fission
Promote
Promote
Promote
Colocalization
Proteomics
238
237
95
PTEN‐L Parkin
Ubiquitin
Ser65
Ser65
Inhibit Mitophagy Suppress Colocalization 229
PTP1D AKAP1
Src
TBD
Tyr530
Activate
Activate
Signaling
Bioenergetics
Promote
Promote
Colocalization 239
TA B L E  1   (Continued)
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fashion.	Concerning	Bcl‐2	proteins	in	the	CNS,	JNK	directly	modifies	
Bcl‐2,	Bad,	 and	Bim	and	 induces	expression	of	apoptotic	proteins,	
like	activator	of	apoptosis	Harakiri	 (HRK)	 to	promote	cell	death	 in	
response	to	neurotoxic	stress.35‐37	Our	research	demonstrated	that	
mitochondrial	 JNK	 could	 phosphorylate	 Bcl‐2	 on	 Ser70	 to	 induce	
emigration	of	Bcl‐2	from	the	OMM,	in	response	to	6‐hydroxydopa‐
mine	exposure	 in	vitro	and	 in	vivo.26,33	The	 loss	of	Bcl‐2	 from	the	
mitochondrial	surface	releases	BH3‐only	proteins	and	Bax	to	engage	
in	mitochondrial	outer	membrane	permeabilization	(MOMP)	initiat‐
ing	apoptosis.38,39	Similarly,	inhibition	of	pro‐survival	OMM‐resident	
Mcl‐1	by	JNK	on	Thr163	and	Ser121	has	been	shown	to	promote	
apoptosis.40,41	The	 inactivation	of	Mcl‐1	by	 JNK	 is	an	event	 impli‐
cated	in	neurotoxic	degenerative	models42	as	well	as	elevated	JNK	
activity	 in	postmortem	neurodegenerative	brain	tissue43,44 reveals 
the	importance	of	mitochondrial	JNK	inhibition	of	pro‐survival	pro‐
teins	in	CNS	disorders.
Alternatively,	 JNK	 has	 been	 shown	 to	 phosphorylate	 Bim	 on	
Ser65	 during	 trophic	 factor	 deprivation	 (TFD)	 as	 part	 of	 apoptosis	
initiation.	Again,	 JNK	phosphorylation	of	Bim	 facilitated	MOMP	 in	
Bax‐dependent	 apoptosis.35,37	Other	BH3‐only	proteins	have	been	
documented	as	JNK	substrates,	including	Bad,	Bid,	and	Noxa.34	JNK	
directly	phosphorylates	Bax	on	Thr167	to	promote	oligomerization	
and	pore	formation	in	the	OMM	leading	to	the	release	of	apoptotic	
contents	of	the	intermembrane	space.45	Smac/DIABLO,	one	of	these	
intermembrane	 components,	 is	 a	 potential	 JNK	 substrate.	Putative	
JNK	 phosphorylation	 of	 Smac/DIABLO	mediates	 the	 release	 from	
mitochondria	 to	 ubiquitinylate	 inhibitors	 of	 apoptosis	 (IAPs)	 for	
degradation	 and	 sustains	 apoptosis.46‐48	 In	 addition	 to	 modifying	
mitochondrial	resident	Bcl‐2	superfamily	proteins,	JNK	acts	perimito‐
chondrially	in	the	cytoplasm	to	induce	translocation	of	proteins	such	
as	Bad	and	Bax	to	mitochondria.	This	 is	achieved	either	by	directly	
phosphorylating	the	proteins	or	by	phosphorylation	of	their	cytosolic	
scaffold,	14‐3‐3,	to	induce	their	release.49‐51	Consequently,	local	JNK	
signaling	on	the	OMM	is	a	crucial	component	of	neuronal	apoptosis.
In	addition	to	regulating	cell	viability,	JNK	signaling	is	associated	
with	bioenergetics	in	the	brain.	The	first	evidence	of	the	regulation	
of	mitochondrial	metabolism	by	local	JNK	signaling	came	from	stud‐
ies	in	the	aging	mouse	brain.52,53	JNK	was	found	to	phosphorylate	
pyruvate	 dehydrogenase	 (PDH)	 complex	 on	 the	 E1α	 subunit	 and	
impaired	PDH	activity.52,53	 JNK‐mediated	 inhibition	of	PDH	 leads	
to	increase	lactic	acid	levels	and	perhaps	contributing	to	energetic	
deficits	in	the	aging	brain.	Our	research	and	studies	in	the	liver	by	
Win	and	colleagues	26,29,54,55	demonstrate	that	JNK	can	impair	the	
activity	of	respiratory	complex	I.	Although	the	precise	mechanism	
has	yet	to	be	determined,	JNK	translocation	to	the	OMM	is	linked	
to	 enhanced	 ROS	 production.	 The	 direct	 inhibition	 of	 both	 PDH	
and	complex	I	by	JNK	is	problematic	given	that	the	substrates	are	
within	 the	mitochondria,	 and	 JNK	had	been	shown	 to	be	present	
F I G U R E  2  c‐Jun	N‐terminal	kinase	(JNK)	on	the	OMM	impacts	apoptosis	and	bioenergetics.	JNK	signaling	has	long	been	linked	to	cell	
death	and	metabolism,	and	only	recently	was	it	realized	that	mitochondrial	JNK	signaling	on	the	OMM	scaffold	protein	Sab	was	critical	
to	the	induction	of	apoptosis	through	the	manipulation	of	proteins	within	the	Bcl‐2	superfamily.	Following	activation,	JNK	translocates	
to	mitochondria.	JNK	interacts	with	and	phosphorylates	the	OMM	scaffold	protein	Sab	most	likely	through	an	interaction	with	the	KIM2	
motif	(K2)	because	the	KIM1	motif	(K1)	may	be	on	the	inner	leaf	of	the	OMM.	In	cases	of	neurotoxin	exposure,	ischemia,	and	cytotoxic	
stress,	mitochondrial	JNK	activity	leads	to	amplification	of	ROS	production,	organelle	dysfunction,	and	cell	death.	Mitochondrial	JNK	can	
impair	complex	I	by	a	yet‐to‐be‐described	mechanism	to	impair	mitochondrial	metabolism	and	engage	ROS	production.	However,	this	
may	be	facilitated	by	signaling	on	the	coiled‐coil	motifs	(CC1/CC2)	of	Sab's	SH3	domain.	Mitochondrial	JNK	can	initiate	apoptosis	through	
phosphorylation	of	Bcl‐2	on	Ser70	inducing	its	emigration	from	mitochondria.	JNK	activity	on	mitochondria	has	also	been	demonstrated	
to	impact	mitochondrial	dynamics	through	phosphorylation	of	Mfn2,	which	leads	to	its	degradation	and	mitochondrial	fission.	JNK	also	
influences	mitochondrial	metabolism	directly	through	the	inhibition	of	PDH	via	phosphorylation	of	the	Eα1	subunit.	In	addition	to	Bcl‐2,	
JNK	can	also	influence	the	activities	of	BH3‐only	proteins	such	as	Bim	to	induce	apoptosis,	and	mitochondrial	JNK	has	been	shown	to	
phosphorylate	Bax	to	induce	permeabilization	of	the	OMM.	The	local	activities	of	mitochondrial	JNK	suggest	it	could	be	a	significant	
physiological	player	in	organelle	health
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on	 the	mitochondrial	 surface.	Therefore,	 JNK	phosphorylates	 the	
substrates	 either	 before	 or	 during	 protein	 import,	 unless	 indirect	
mechanisms	 may	 be	 responsible	 for	 the	 inhibition.	 This	 appears	
to	be	the	case	for	complex	I,	as	Win	and	associates	found	that	in‐
hibitors	of	 intramitochondrial	Src	associate	with	Sab.29	Upon	JNK	
binding/phosphorylation	 of	 Sab,	 Src	 inhibitor	 SHP‐1,	 a	 tyrosine	
phosphatase,	is	responsible	for	dephosphorylating	Src	Tyr419	inac‐
tivating	the	kinase	and	reducing	complex	I	activity.29	These	studies	
implicate	mitochondrial	 JNK	 as	 a	 crucial	metabolic	 regulator	 and	
illustrate	 the	 possibility	 of	 transmembrane	 signaling	 cascades	 at	
mitochondria,	which	may	serve	as	intra‐	and	extra‐organelle	com‐
munication	circuits.
Recently,	 JNK	 signaling	 has	 been	 linked	 to	 mitochondrial	 dy‐
namics	 and	 quality	 control	 through	 the	 phosphorylation	 of	OMM	
substrates,56,57	 and	 although	 this	work	was	 not	 performed	 in	 the	
CNS,	 the	 implications	of	 impaired	mitophagy	and	 JNK	signaling	 in	
neurodegenerative	disorders	warrant	 the	mention	of	 this	 relation‐
ship.24,43,58,59	Specifically,	 JNK2	was	 found	to	 translocate	 to	mito‐
chondria	and	phosphorylate	the	mitochondrial	form	of	the	alternate	
reading	frame	tumor	suppressor	 [ARF	 (smARF,	small	ARF)]	 leading	
to	ubiquitination	and	degradation	by	the	proteasome.56	Diminished	
smARF	levels	raised	the	steady‐state	levels	of	p62,	a	mediator	of	au‐
tophagic‐lysosomal	degradation,	which	was	more	readily	degraded	
in	the	absence	of	JNK2.56	Ablation	of	JNK2	produced	higher	levels	
of	basal	mitophagy	and	autophagy	and	was	typified	by	high	smARF	
and	low	p62	(a	result	of	increased	autophagy)	levels.56	Mitochondrial	
JNK	 activity	 has	 also	 been	 linked	 to	 the	 turnover	 of	 mitofusin‐2	
(Mfn2)	 but	 not	Mfn1.	 JNK	was	 shown	 to	 phosphorylate	Mfn2	 on	
Ser27,	which	promoted	the	ubiquitination	and	proteasomal	degrada‐
tion	of	Mfn2.57	The	loss	of	Mfn2	contributed	to	mitochondrial	frag‐
mentation	in	human	U2OS	osteosarcoma	cells.
Additionally,	the	loss	of	Mfn2	was	associated	with	induction	of	
apoptosis	to	genotoxic	stress	induced	by	doxorubicin.57	Therefore,	
it	is	possible	that	local	JNK	signaling	can	contribute	to	the	turnover	
of	 stressed	mitochondria	 by	 enhancing	 fission	 and	 degradation	 of	
problematic	organelles.	Collectively,	mitochondrial	JNK	is	a	crucial	
regulator	of	mitochondrial	form	and	function	as	well	as	cellular	via‐
bility	in	the	CNS.
3.2 | Extracellular regulated kinase
The	extracellular	regulated	kinase	(ERK)	exists	as	numerous	isoforms	
in	the	brain	with	ERK1/2	being	the	most	well‐characterized	species	
of	the	family.	Similar	to	JNK,	ERK1/2	activity	on	the	mitochondria	
has	been	reported	in	the	hippocampus,60	implicated	in	PD,61 and is 
associated	with	 the	post‐translational	modification	of	Bcl‐2	 family	
members 62	and	organelle	physiology.63,64	Although	ERK1/2	activ‐
ity	generally	is	thought	to	be	pro‐survival,	prolonged	ERK1/2	signal‐
ing	can	be	linked	to	cell	death	as	well.62	ERK1/2	signaling	outcomes	
are	 stimulus‐	 and	 cell‐type‐dependent,	 as	 is	 the	 case	 with	 most	
MAPKs.	 Recently,	 ERK1/2	 interaction	with	 heat	 shock	 protein	B1	
(HSPB1)	was	 shown	 to	 facilitate	 the	phosphorylation	of	 the	BH3‐
only	protein	Bim	leading	to	its	degradation	and	ultimately	impairing	
ER	stress‐induced	apoptosis.65	 Intriguingly,	HSPB1	mutations	from	
Charcot‐Marie‐Tooth	disease	exhibit	high	levels	of	BIM	and	are	more	
vulnerable	to	ER	stress‐induced	cell	death	than	their	wild‐type	coun‐
terparts.65	 However,	 ERK1/2	 phosphorylation	 of	 Bcl‐2	 and	Mcl‐1	
has	been	described	to	have	conflicting	effects	in	the	literature.66	For	
example,	ERK1/2	phosphorylation	of	Bcl‐2	can	prevent	Bcl‐2	func‐
tion	 activating	 neuronal	 apoptosis	 67‐70;	 meanwhile,	 other	 reports	
indicate	 that	 ERK1/2	 phosphorylation	 of	 Bcl‐2	 promotes	 the	 pro‐
tein's	anti‐apoptotic	activities.71‐73	Similar	studies	have	been	noted	
for	Mcl‐1	with	ERK1/2	phosphorylation	both	inhibiting	and	enhanc‐
ing	Mcl‐1	 anti‐apoptotic	 functions.74	 Thus,	 considerable	 attention	
should	be	paid	to	the	cellular	and	stress	contexts	of	ERK1/2	signal‐
ing	when	examining	Bcl‐2	phosphorylation	especially	in	the	diverse	
cellular	populations	of	the	CNS.
ERK1/2	activity	has	 also	been	 implicated	as	 a	 regulator	of	mi‐
tochondrial	 dynamics.	Mitochondrial	 ERK2	 translocation	 emulates	
6‐OHDA‐mediated	effects	on	mitophagy.61	Additionally,	mitochon‐
drially	 localized	 ERK1/2	 can	 phosphorylate	 dynamin‐related	 pro‐
tein	1	 (Drp‐1)	 and	Mfn1	 to	 impair	 fusion.	 It	was	 reported	 in	2015	
by	two	independent	studies	that	ERK2	could	phosphorylate	Drp‐1	
on	 Ser616	 and	 promote	 mitochondrial	 fission.75	 This	 event	 was	
shown	to	be	driven	by	the	Ras	oncogene	and	necessary	for	tumor	
growth.	 ERK2‐Drp‐1	 activation	 was	 later	 revealed	 to	 be	 required	
for	 cellular	 programming	 during	 development.75	 Also,	 in	 2015,	
Pyakural	 and	 colleagues	 demonstrated	 that	 ERK1/2	 phosphoryla‐
tion	 of	Mfn1	 on	 Thr562	 impaired	 the	 organelle	 docking	 activities	
of	 Mfn1.76	 Expression	 of	 constitutively	 active	 MAPK/ERK	 kinase	
(MEK)	resulted	in	mitochondrial	fragmentation.	Also,	ERK1/2	phos‐
phorylation	of	Mfn1	also	sensitized	cells	to	apoptotic	stimuli	impli‐
cating	mitochondrial	ERK	signaling	in	both	functional	and	cell	death	
responses.76
ERK1/2	 signaling	 can	 impact	 bioenergetics	 and	 mitochondrial	
metabolism	as	well.	Recent	reports	have	suggested	that	ERK1/2	is	
necessary	 to	 induce	glycolysis.	One	proposed	mechanism	 for	ERK	
regulation	 of	 glycolysis	 involves	 the	 phosphorylation	 of	 phospho‐
glycerate	kinase	1	(PGK‐1)	by	ERK1/2	on	Ser	203.77	This	phosphor‐
ylation	 event	 induces	 mitochondrial	 PGK‐1	 to	 become	 a	 protein	
kinase	 that	 phosphorylates	 and	 activates	 PDH	 kinase	 1	 (PDHK1)	
on	 Thr338.	 PDHK1,	 in	 turn,	 phosphorylates	 PDH	 inhibiting	 en‐
zyme	 activity	 and	 promoting	 glycolysis.77	 Another	 recent	 report	
demonstrates	 that	 in	 the	presence	of	mutations	 in	neurofibromin,	
a	 hallmark	 of	 neurofibromatosis	 type	 1	 (a	 condition	 that	 predis‐
poses	 patients	 to	 tumor	 formation),	 ERK1/2	 phosphorylates	 the	
chaperone	 TRAP1.78	 Phosphorylation	 of	 TRAP1	 impairs	 succinate	
dehydrogenase	(SDH)	leading	to	the	accumulation	of	succinate	and	
tumor	progression.78	 The	most	widely	 recognized	metabolic	 inter‐
action	 is	 between	ERK1/2	and	 the	 steroidogenic	 acute	 regulatory	
protein	 (StAR).79	 ERK1/2	 phosphorylates	 StAR	 on	 Ser	 232,	which	
stabilizes	the	protein	in	mitochondria	and	sustains	steroid	synthesis.	
ERK	activity,	along	with	protein	kinase	A	(PKA),	is	required	for	max‐
imal	steroid	production	in	Leydig	cells.80	These	studies	collectively	
implicate	local	ERK	signaling	in	the	regulation	of	mitochondrial	form	
and	function.
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3.3 | P38 kinases
The	p38	kinases,	in	particular	p38α	(MAPK14),	have	been	implicated	
in	the	pathogenesis	of	neurodegenerative,	and	pharmacological	in‐
hibitors	of	p38	have	been	shown	to	protect	against	neuronal	loss	in	
preclinical	models	of	neurodegenerative	disorders	 in	 the	CNS.81,82 
The	basis	 for	 these	 studies	 stems	 from	 the	 involvement	of	p38	 in	
apoptosis.	The	general	effect	of	p38	signaling	affects	the	levels	of	
Bcl‐2	(decrease)	and	Bax	(increase)	 levels	on	mitochondria	through	
transcriptional	 and	 post‐transcriptional	means	 contributing	 to	 po‐
tentiating	cells	toward	apoptosis.83	However,	p38	direct	effects	on	
Bcl‐2	 superfamily	 proteins	 remain	 elusive.	 Nonetheless,	 p38	 has	
been	 shown	 to	migrate	 to	mitochondria	 follow	 stress	 (such	 as	 is‐
chemia	or	oxidative	stress)	in	cardiac	tissue.84	Court	and	colleagues	
proposed	 that	p38γ	 interacts	with	outer	mitochondrial	 protein	25	
(OMP25)	that	impaired	p38γ	activity	in	vitro.85	To	date,	mitochon‐
drial	p38,	 specifically	p38γ,	has	been	shown	to	converge	on	mito‐
chondria	 and	 phosphorylate	 Sab,	 a	well‐established	mitochondrial	
scaffold	protein	for	JNK.86	Investigators	demonstrated	in	vitro	p38γ 
phosphorylated	 Sab	 on	 Ser321,86	 which	 is	 in	 KIM1,	 preceding	 a	
transmembrane	motif.29	This	places	Ser321	within	the	mitochondria,	
and	no	documentation	of	p38	within	mitochondria	has	been	made	
raising	questions	to	the	contributions	of	 this	PTM	to	physiological	
mitochondrial	 signaling.	 Regardless,	 p38	 is	 a	 significant	 player	 in	
signaling	regulating	mitochondrial	health.
4  | PROTEIN KINASE A ,  G ,  C  (AGC 
KINASES)
The	AGC	kinase	family	has	two	members	present	on	the	OMM	that	
can	 influence	 organelle	 physiology:	 PKA	 and	 isoforms	 of	 PKC.87 
PKA	 is	 likely	 the	 most	 well‐investigated	 cytosolic	 kinase	 on	 the	
mitochondrial	 surface,	 as	 it	 is	 well	 documented	 to	 play	 a	 role	 in	
sustaining	organelle	health.88	Meanwhile,	the	role	of	PKC	on	mito‐
chondria	is	more	complicated	with	distinct	variants	contributing	to	
the	divergent	aspects	and	outcomes	of	mitochondrial	function	and	
health.89,90
4.1 | Protein kinase A (PKA)
Mitochondrial	 PKA	 has	 long	 been	 associated	 with	 mitochondria	
through	its	 interaction	with	scaffold	proteins	of	the	A‐kinase	an‐
choring	proteins	(AKAP)	family	in	particularly	AKAP‐1	(or	D‐AKAP	
as	 often	 used	 for	 the	mitochondrial	 PKA	 scaffold).91,92	 PKA	 has	
been	documented	to	affect	numerous	mitochondrial	proteins	rang‐
ing	from	bioenergetics	to	dynamics	to	redox	homeostasis	and	cell	
survival.93	The	substrates	for	mitochondrial	PKA	have	been	iden‐
tified	 both	 on	 and	within	mitochondria	 suggesting	 the	 ability	 of	
mitochondrial	 PKA	 to	 transcend	 the	 OMM.	 Mitochondrial	 PKA	
signaling	is	thought	to	be	mainly	beneficial	to	the	organelle	facili‐
tating	 essential	 functions	 such	 as	 protein	 import	while	 impeding	
processes	such	as	fission	and	apoptosis.94	Increasing	the	levels	of	
mitochondrial	PKA	through	genetic	and	pharmacological	manipu‐
lation	has	been	shown	to	be	neuroprotective	in	preclinical	models	
of	neurodegenerative	diseases,	 specifically	PD.95‐97	Furthermore,	
adding	an	OMM	localization	signaling	to	the	N	terminus	of	PKA	can	
diminish	the	effects	of	mitochondrial	toxins	and	stress.95,96	These	
protective	effects	are	best	represented	by	the	mitochondrial	sub‐
strates	of	PKA	on	the	OMM	described	immediately	below	and	in	
Figure	3.
The	 most	 recent	 analysis	 of	 PKA	 with	 concerning	 OMM	 sig‐
naling	 and	 organelle	 physiology	 have	 involved	 the	 molecular	 ma‐
chinery	of	mitochondrial	 dynamics.98	Mitochondrial	PKA	was	 first	
linked	 to	 organelle	 dynamics	 through	 phosphorylation	 of	Drp‐1.99 
PKA	phosphorylation	 of	Drp‐1	 on	 Ser637	 impairs	 the	 function	 of	
Drp‐1	preventing	 fission,	which	 results	 in	elongated	mitochondria.	
Ablation	 of	 Drp‐1	 Ser637	 or	 dephosphorylation	 by	 calcineurin	
was	 found	 to	activate	Drp‐1	 leading	 to	organelle	 fragmentation.99 
Increasing	 mitochondrial	 PKA	 was	 found	 to	 also	 protect	 neurons	
from	neurotoxin‐induced	cell	death	in	part	through	phosphorylation	
of	Drp‐1.95	 The	manipulation	of	Drp‐1	by	PKA	could	be	crucial	 to	
maintaining	mitochondrial	integrity	and	health	and	may	affect	mito‐
chondrial	transport	in	neurons	as	well	as	mitochondrial	 integration	
at	synapses.96,100‐103
PKA	activity	on	the	OMM	has	been	shown	to	influence	the	sta‐
bility	of	PTEN‐induced	kinase‐1	(PINK1),104	which	is	a	crucial	com‐
ponent	of	mitophagy,	through	the	phosphorylation	of	proteins	in	the	
mitochondrial	contact	site	and	cristae	organizing	system	(MICOS).105 
Increasing	PKA	mitochondrial	activity	was	found	to	prevent	Parkin	
recruitment	to	depolarized	mitochondria	by	decreasing	PINK1	lev‐
els.	 Investigators	determined	that	PKA	phosphorylation	of	MIC60,	
a	MICOS	component,	on	Ser528	destabilized	PINK1	in	the	OMM	by	
an	 unknown	mechanism	 leading	 to	 its	 degradation.105	Meanwhile,	
mitochondrial	PKA	phosphorylation	of	MIC19	on	Thr11	was	found	
to	 impair	 Parkin	 recruitment	 to	 mitochondria.	 Also,	 elevating	 the	
levels	of	PKA	on	mitochondria	reduced	the	amount	of	organelle	de‐
polarization	in	cultures.105	While	these	results	indicate	that	PKA	is	
involved	 in	 the	 regulation	of	mitophagy,	 it	 is	exciting	 to	 think	 that	
coregulation	 of	 energetic	 and	 communication	 components	 of	 in	
MICOS	can	be	manipulated	by	signal	transduction	pathways	to	 in‐
fluence	organelle	 turnover	and	health.	Perhaps,	 this	 interplay	may	
represent	a	new	therapeutic	avenue	for	the	treatment	of	neurode‐
generative	disorders,	such	as	PD.97,104
Mitochondrial	 PKA	 has	 been	 long	 associated	 with	 respiratory	
function	and	efficiency	of	complexes	in	the	ETC	through	the	manip‐
ulation	of	protein	import	and	the	direct	phosphorylation	of	protein	
subunits	of	 respiratory	enzyme	 systems.106‐109	Mitochondrial	PKA	
has	been	shown	to	directly	affect	the	functions	of	ETC	complexes	
I,	IV,	and	V	to	promote	respiration	and	ATP	synthesis.106‐108	A	com‐
plex	 I	 target	 of	 PKA	 is	NADH:ubiquinone	 oxidoreductase	 subunit	
S4	 (NDUFS4).	 PKA	 phosphorylation	 of	 NDUFS4	 on	 Ser173	 pro‐
motes	 interaction	with	 the	Hsp70	 chaperone	 facilitating	NDUFS4	
import	into	mitochondria	and	integration	with	other	complex	I	sub‐
units.110	Consequently,	mutations	that	disrupt	the	NDUFS4	Ser173	
phosphorylation	 site	 are	 linked	 to	 complex	 I	 dysfunction	 in	 the	
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mitochondrial	encephalomyopathy	Leigh	syndrome,	a	neuromuscu‐
lar	 disorder	 associated	with	 impaired	mitochondria	 function.111,112 
In	addition	to	modification	of	NDUFS4,	mitochondrial	PKA	also	in‐
fluences	 the	protein	 stability	 of	 complex	 I	 by	 inhibiting	 intramito‐
chondrial	 proteases	 capable	 of	 degrading	 complex	 I	 constituents,	
NDUFA9,	NDUFS4,	and	NDUFV2.113
Pharmacological	inhibition	of	mitochondrial	soluble	adenylyl	cy‐
clase	 (sAC)	 results	 in	 the	proteolytic	degradation	of	 these	compo‐
nents	due	to	diminished	local	PKA	activity.113	Alternatively,	complex	
IV	(cytochrome	c	oxidase)	subunits	can	be	directly	phosphorylated	
by	mitochondrial	PKA,	and	distinct	modifications	can	serve	to	mod‐
ulate	 complex	 function.114	 For	 example,	 PKA	 phosphorylation	 of	
complex	 IV	 subunit	 I	 on	 Ser58	 nullifies	 ATP‐dependent	 inhibition	
of	complex	IV	sustaining	activity,	whereas	PKA	phosphorylation	of	
subunits	I,	 IV‐1,	and	Vb	during	hypoxia	triggers	degradation	of	the	
proteins	and	diminishes	complex	IV	activity.115,116
Similarly,	mitochondrial	 PKA	 can	modulate	 complex	V	 activity.	
Local	PKA	phosphorylation	of	ATPase	inhibitory	factor	1	(AIF1)	on	
Ser39	prevents	the	interaction	between	AIF1	and	complex	V	main‐
taining	ATP	synthase	activity.117,118	Also,	decreasing	PKA	activity	in	
mitochondria	can	lead	to	the	proteolytic	degradation	of	complex	V	
components	resulting	in	less	ATP	synthesis.118,119	The	proximity	of	
PKA	to	the	bioenergetic	machinery	makes	the	kinase	a	useful	regu‐
lator	of	ATP	production	and	the	ETC	Furthermore,	the	relationship	
between	ATP	production	and	mitochondrial	PKA	activity	extends	to	
signaling	 transduction	pathways.	Wherein,	activation	of	 the	AMP‐
dependent	protein	kinase	 (AMPK)	can	phosphorylate	and	stabilize	
D‐AKAP	 to	 engage	 ATP	 production	 and	 promote	 cell	 survival.120 
Mitochondrial	PKA	can	be	considered	to	be	a	crucial	component	of	
ETC	and	mitochondrial	bioenergetic	regulation.
Mitochondrial	PKA	 is	 an	embedded	 regulator	of	mitochondrial	
antioxidant	 capacity.	Mitochondrial	 PKA	 can	phosphorylate	 a	 glu‐
tathione	 S‐transferase	 variant	 (GSTA4‐4)	 on	 Ser189.121	 Similar	 to	
NDUFS4,	 PKA	phosphorylation	 of	GSTA4‐4	 facilitates	 its	 interac‐
tion	with	Hsp70	and	subsequent	 import	 into	mitochondria.121	This	
event	 enhances	 glutathione	 production	 in	 mitochondria	 and	 in‐
creases	antioxidant	capacity	within	organelles.
While	 mitochondrial	 PKA	 activity	 can	 increase	 the	 import	 of	
proteins	 by	 promoting	 interactions	 with	 chaperones	 like	 Hsp70,	
local	 PKA	 activity	 can	 phosphorylate	 protein	 transporters	 on	 the	
mitochondrial	surface	and	impede	their	functions.122,123	PKA	phos‐
phorylation	 of	 TOM22	 on	 Thr76124	 and	 TOM40	 on	 Ser54125 can 
prevent	 transport	 of	 the	 proteins	 into	 mitochondria;	 additionally,	
the	 PKA	 phosphorylation	 of	 TOM22	 can	 also	 impair	 its	 transport	
functions.124	Similarly,	PKA	can	phosphorylate	TOM70	on	Ser174,	
which	 inhibits	 TOM70	 receptor‐type	 activities	 toward	 chaperone	
functions	such	as	Hsp70.126	To	 reconcile	 the	distinctions	between	
PKA's	facilitation	and	inhibition	of	protein	import	into	mitochondria,	
the	 levels,	 and	duration	 as	well	 as	 the	 context	 of	 PKA,	 as	well	 as	
other	signaling	events,	should	be	taken	into	account	when	observing	
mitochondrial	outcomes.
Finally,	 PKA	 signaling	 on	 mitochondria	 was	 found	 to	 impair	
apoptosis.127‐130	 Mitochondrial	 PKA	 can	 phosphorylate	 Bad	 on	
Ser112,	 and	 Ser155	 has	 been	 shown	 to	 alleviate	 the	 inhibitory	
F I G U R E  3  Mitochondrial	PKA	is	a	central	mediator	of	mitochondrial	health.	PKA	is	a	well‐documented	regulator	of	mitochondrial	form	
and	function.	The	actions	of	PKA	can	be	inhibitory	to	local	processes	or	activate	others.	PKA	interacts	with	AKAP1	(D‐AKAP)	on	the	
mitochondrial	surface.	PKA	OMM	activity	can	phosphorylate	and	impair	the	activity	of	Drp‐1	preventing	fission	and	resulting	in	elongating	
mitochondria.	Similarly,	mitochondrial	PKA	activation	of	MIC60	can	influence	PINK1	stability	on	the	OMM.	Phosphorylation	of	MIC60	
leads	to	the	decline	in	PINK1	levels	and	prevent	Parkin	recruitment.	This	could	be	a	potential	mechanism	for	PKA	to	protect	healthy	
mitochondria.	Mitochondrial	PKA	can	phosphorylate	and	inhibit	the	apoptotic	actions	of	Bad.	Alternatively,	PKA	can	increase	the	function	
of	mitochondrial	proteins.	Mitochondrial	PKA	can	also	phosphorylate	VDAC	and	contribute	to	stress‐induced	mitochondrial	depolarization.	
Alternatively,	PKA	phosphorylation	of	OMM	transporters	such	as	TOM22	facilitates	the	import	of	nuclear‐encoded	proteins	(IE,	subunits	of	
the	respiratory	chain).	PKA	phosphorylation	can	coincide	with	protein	import,	as	in	the	case	of	NDUFS4,	a	complex	I	subunit	can	enhance	
protein	function	and	the	efficiency	of	ETC	complexes.	These	studies	indicate	mitochondrial	PKA	is	required	for	healthy	mitochondria
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effects	of	Bad	on	anti‐apoptotic	proteins	Bcl‐2	and	Bcl‐xL	promot‐
ing	 cell	 survival.131	 However,	 PKA	 activity	 had	 also	 been	 linked	
to	apoptosis	through	the	phosphorylation	and	stabilization	of	Bim	
on	Ser83,130	and	PKA	phosphorylation	of	Bax	on	Ser60	promotes	
Bax	translocation	to	mitochondria	and	MOMP.132	As	with	protein	
import,	cell	context	and	the	dose/duration	of	signaling	should	be	
considered	when	evaluating	local	outcomes	of	mitochondrial	PKA	
signaling.
Given	the	reliance	of	mitochondria	on	local	PKA	signaling,	it	is	
not	surprising	to	find	that	perturbations	 in	PKA	signaling	can	be	
found	 in	 neurodegenerative	 disorders	 typified	 by	mitochondrial	
dysfunction.133‐136	In	preclinical	models	of	PD,	there	is	diminished	
PKA	 signaling	 that	 coincides	with	data	 collected	 in	postmortem	
brains.	Increasing	the	levels	of	mitochondrial	PKA	either	through	
increasing	 AKAP‐1,	 targeting	 PKA	 to	 mitochondria,	 or	 pharma‐
cological	activation	of	PKA	can	offset	mitochondrial	dysfunction	
and	 neuronal	 cell	 death	 in	 PD	models,	 in	 particular,	 those	 with	
PINK1	 deficiency.96,97,99,104	 Similar	 to	 PD,	 dysregulation	 of	 PKA	
signaling	has	been	noted	in	AD	and	models	with	elevated	amyloid	
beta.93	Defects	in	mitochondrial	health	and	trafficking	in	AD‐like	
conditions	 were	 alleviated	 by	 the	 reintroduction	 of	 PKA.93,135 
These	 results	 indicate	 that	 diminished	 PKA	 signaling	 is	 a	 com‐
ponent	 of	 neurodegenerative	 disorders	 and	 restoring	 local	 PKA	
activity	 could	 be	 a	means	 to	 impede	 the	 pathogenesis	 of	 these	
conditions.
4.2 | Protein kinase C (PKC)
Protein	kinase	C	isoforms	are	emerging	as	potential	regulators	of	mi‐
tochondrial	function	in	the	areas	of	metabolism	and	apoptosis137‐139; 
however,	 a	 complicating	 factor	 could	 be	 that	 distinct	 activities	 of	
PKC	isoform	could	have	discrete	impacts	on	mitochondrial	physiol‐
ogy.	To	date,	 three	 isoforms	of	PKC,	PKCα,140	PKCδ,	 and	PKCε,141 
have	 shown	 mitochondrial	 localization.	 PKCδ	 is	 associated	 more	
with	 neurodegeneration	 and	neuroinflammation,142,143	while	PKCε 
has	been	demonstrated	to	be	more	protective.144
PKCδ	has	been	shown	to	undergo	cleavage	by	caspase	activity	
in	response	to	stress,	and	the	cleaved	species	of	PKCδ	contributes	
to	 stress‐induced	 mitochondrial	 dysfunction.	 PKCδ‐induced	 mito‐
chondrial	dysfunction	 is	also	associated	with	dopaminergic	neuro‐
toxicity	 in	 preclinical	 PD	models.143,145	 Although	 the	 outcomes	 of	
mitochondrial	 PKCδ	 signaling	 affect	 apoptosis,	 respiration,	 mem‐
brane	potential,	ROS	production,	antioxidant	capacity,	and	organelle	
dynamics,146‐148	only	Drp‐1	has	been	shown	to	 interact	with	PKCδ 
and	contribute	to	organelle	fragmentation.149	Further	investigation	
is	needed	to	elaborate	on	PKCδ	functions	at	mitochondria.
PKCε	 also	 demonstrates	 mitochondrial	 localization	 in	 re‐
sponse	to	cerebral	ischemia	and	increases	sirtuin	5	(Sirt5)	levels.150 
Outside	of	 this	 report,	most	of	 the	work	has	been	performed	 in	
non‐CNS	tissues.	PKCε	has	been	shown	to	phosphorylate	complex	
IV	and	increase	its	activity	in	the	heart	and	kidney	in	response	to	
stress.138,151	Also,	PKCε	has	been	shown	to	phosphorylate	and	reg‐
ulate	cardiac	sodium	channels	 in	 response	 to	metabolic	changes.	
Concerning	the	CNS,	PKCε	phosphorylation	has	been	shown	to	in‐
crease	the	activity	of	endothelin	converting	enzyme	(ECE),	which	
is	responsible	for	amyloid	beta	clearance,	via	an	N‐terminal	mod‐
ification	site.152	This	would	indicate	that	PKCε	may	be	downregu‐
lated	 in	Alzheimer's	disease,153	and	restoring	PKCε	activity	could	
be	neuroprotective	similar	to	how	PKCε	activity	is	observed	in	car‐
diac	tissue.
5  | PARKINSON'S DISEASE RELEVANT 
PROTEIN KINASES
Protein	 kinases	 have	 been	 implicated	 in	 the	 pathogenesis	 of	
Parkinson's	 disease	 (PD),	 and	discrete	 changes	 in	protein	 kinase	
activity	have	been	noted	for	cytosolic	kinases	 like	PKA	and	JNK	
that	 promoted	 disease	 physiology	 (described	 above).	 However,	
two	kinases	in	particular	are	linked	to	familial	and	idiopathic	cases	
of	 PD	 and	 have	 populations	 present	 on	 the	 OMM.	Mutants	 of	
the	 leucine‐rich	 repeat	 kinase	 2	 (LRRK2)	 and	 the	 PTEN‐induc‐
ible	kinase	1	(PINK1)	can	profoundly	impact	organelle	physiology	
contributing	to	PD	pathogenesis	and	progression.	(summarized	in	
Figure	4).
5.1 | Leucine‐rich repeat kinase 2 (LRRK2)
A	protein	kinase	 implicated	 in	 familial	and	sporadic	cases	of	PD	 is	
leucine‐rich	repeat	kinase	2	 (LRRK2),	wherein	mutations	 in	LRRK2	
have	been	shown	to	increase	kinase	activity.154	LRRK2	and	mutant	
LRRK2	 localize	to	 intracellular	membranes	 in	the	rodent	brain	and	
human	 cells.	 Intriguingly,	 approximately	 10%	 of	 LRRK2	 has	 been	
shown	to	localize	to	the	OMM,155	and	there	is	increasing	evidence	
for	mutant	LRRK2	to	directly	impact	mitochondrial	physiology	and	
apoptotic	machinery	(reviewed	in	156).	Also,	mutant	LRRK2‐induced	
mitochondrial	dysfunction	has	been	noted	in	numerous	experimen‐
tal	models	and	PD	patients.
Increased	LRRK2	kinase	activity	has	been	linked	to	the	phosphor‐
ylation	of	and	interactions	with	mitochondrial	proteins	implicated	in	
organelle	dysfunction	in	PD157	including	the	uncoupling	proteins	in	
neurons,158	 Bcl‐2	 proteins,159	 Drp‐1,160‐163	Miro,164	 the	mitochon‐
drial	 calcium	uniporter	 (MCU),165	 and	 peroxiredoxin	 3	 (PRDX3).166 
Early	 studies	 found	 that	 expression	 of	 the	 most	 common	 clinical	
LRRK2	mutant	G2019S	could	impact	mitochondrial	morphology	in‐
creasing	mitochondrial	 fission.	The	enhanced	 fission	was	 found	 to	
be	a	result	of	interaction	between	LRRK2:G2019S	and	Drp‐1.160	The	
recruitment	of	Drp‐1	to	mitochondrial	and	subsequent	fission	in	PD	
patient‐derived	fibroblasts	and	human	SH‐SY5Y	cells	was	found	to	
be	dependent	upon	LRRK2	kinase	 activity.161,162	Given	 the	 recent	
identification	 of	 Rab	 GTPases,	 specifically	 Rab7,167	 as	 bonafide	
LRRK2	 substrates,168	 it	 is	 likely	 that	mutant	 LRRK2	 activity	 could	
drive	mitochondrial	 fragmentation	observed	 in	PD	patients	by	 as‐
sembling	the	protein	machinery	and	activating	membrane	fusion.169
LRRK2:	G2019S	expression	 in	HeLa	 cells	 revealed	 that	 LRRK2	
mutants	 interacted	 with	 and	 phosphorylated	 Bcl‐2	 on	 Thr56	 to	
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increase	 autophagy	 and	 mitochondrial	 mass.159	 However,	 Hsieh	
and	colleagues	reported	that	LRRK2	in	iPSC‐derived	neurons	facili‐
tate	the	interaction	of	damaged	mitochondria	with	the	microtubule	
motor	accessory	protein	Miro	paving	the	way	for	clearance	of	de‐
polarized	organelles;	consequently,	LRRK2:G2019S	impedes	the	in‐
teraction	of	Miro	with	damaged	mitochondria	slowing	the	clearance	
of	potentially	detrimental	organelles	from	neurons.164	Additionally,	
LRRK2:G2019S	is	linked	to	aberrant	mitochondrial	trafficking,	spe‐
cifically	axonal	transport,	through	inhibition	of	the	Miro‐mitochon‐
drial	 interaction.164	 Fibroblasts	 from	 PD	 patients	 do	 exhibit	more	
mitochondrial	fragmentation	and	enhanced	mitophagy	initially	com‐
pared	to	control	cells.	Thus,	the	role	of	LRRK2	in	mitophagy	will	re‐
quire	a	closer	examination.169
Lastly,	 enhanced	 LRRK2	 kinase	 activity	 can	 affect	 ROS	 levels	
and	production	through	manipulation	of	mitochondrial	substrates.	
While	 LRRK2	 mutants	 are	 known	 to	 alter	 ETC	 function,	 LRRK2	
mutants	have	been	found	to	alter	antioxidant	capabilities	 in	mito‐
chondria.	For	example,	LRRK2:G2019S	was	found	to	phosphorylate	
and	 impair	 PRDX3	 in	 drosophila	 brains	 diminishing	 organelle	 oxi‐
dant	handling	capacity.166	Alternatively,	patient‐derived	fibroblasts	
and	SH‐SY5Y	cells	 expressing	LRRK2:G2019	have	elevated	 levels	
of	uncoupling	protein	expression,	namely	UCP2	and	UCP4,	respec‐
tively.158	Further,	the	increased	expression	of	UCPs	linked	to	kinase	
activity,	 as	 the	 elevation	 in	 UCP	mRNA	was	 reversed	 by	 LRRK2	
inhibitors.	 The	 increase	 in	 UCP	 appears	 to	 be	 neuroprotective	
because	 UCP	 inhibitors	 exacerbate	 LRRK2	 mutant	 pathology158 
and	overexpression	of	UCP2	protects	against	PD‐relevant	neuro‐
toxins,	such	as	MPTP.158	Thus,	UCPs	may	protect	by	diminishing	the	
production	of	ROS	by	aberrant	ETC	function	and	compensate	for	
diminished	organelle	antioxidant	capacity.	A	recent	study	demon‐
strates	 that	mutant	 LRRK2	 can	 influence	 the	MCU	 increasing	 in‐
traorganellar	 Ca2+	 concentrations.165	 This	 elevation	 in	 Ca2+ may 
induce	ROS	production	 in	LRRK2	mutant	cells.	These	studies	col‐
lectively	demonstrate	that	LRRK2	is	a	crucial	component	of	mito‐
chondrial	regulation.
5.2 | PTEN‐induced kinase 1 (PINK1)
PTEN‐induced	putative	 kinase	1	 (PINK1)	 has	drawn	 significant	 at‐
tention	due	to	its	role	in	mitophagy	and	association	with	PD.	Under	
basal	 conditions,	PINK1	 is	 transported	 into	 the	mitochondrial	ma‐
trix	through	the	translocases	of	the	outer	membrane,	TOM20	and	
TOM23,	the	translocation	channel	TOM40,	and	the	translocase	of	
inner	membrane	TIM23.	 Inside	 the	mitochondrial	matrix,	PINK1	 is	
cleaved	by	a	mitochondrial	processing	peptidase	(MPP)	and	a	rhom‐
boid	protease,	PARL.170‐172	The	cleaved	PINK1	is	then	re‐transported	
into	the	cytosol	and	degraded	by	the	ubiquitin	(Ub)	proteasome	sys‐
tem	(UPS).171
When	PINK1	transport	 through	TOM	 is	hindered,	 for	 instance	
by	 a	 depolarized	 mitochondria	 membrane	 potential	 (MMP),	 it	
F I G U R E  4  Parkinson's	disease‐related	protein	kinases	impact	mitochondrial	physiology.	PD	is	associated	with	mitochondrial	dysfunction,	
and	numerous	proteins	implicated	in	familial	PD	or	disease	pathogenesis	exhibit	mitochondrial	localization	or	influence	organelle	physiology.	
(A)	Loss‐of‐function	mutations	in	PINK1	are	found	in	familial	PD	patients.	PINK1	accumulates	at	the	OMM	following	mitochondrial	
depolarization	leading	to	its	activation	by	autophosphorylation.	An	activated	PINK1	can	then	phosphorylation	ubiquitin	on	Ser65	(Ub—
orange	circles)	and	activate/recruit	Parkin	to	stress,	aged,	or	damaged	mitochondrial	to	facilitate	their	elimination	by	mitophagy.	(B)	
Mutations	in	LRRK2	increase	kinase	activity	and	occur	in	both	familial	and	sporadic	PD	cases.	Increased	LRRK2	activity	can	be	linked	to	
changes	in	autophagic	flux	through	the	manipulation	of	Bcl‐2	and	inhibition	of	Miro,	whereby	LRRK2	can	interact	with	and	sequester	Miro	
preventing	turnover	and	trafficking	of	damaged	organelles.	LRRK2	mutants,	such	as	G2019S,	are	also	associated	with	changes	in	Ca2+ 
homeostasis	through	perturbation	of	mitochondrial	calcium	uniporter	(MCU)	and	decreased	oxidative	stress	tolerance	by	phosphorylation‐
dependent	impairment	of	PRDX3.	LRRK2	variants	are	found	to	affect	bioenergetics	by	inhibiting	complex	I	(not	shown)	and	increasing	UCP	
abundance	and	stability.	The	kinases	represent	direct	effectors	of	PD‐induced	mitochondrial	dysfunction
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accumulates	 on	 the	 OMM	 and	 auto‐phosphorylates	 at	 Ser228	
and	 Ser402.173,174	 The	 activated	PINK1	phosphorylates	Ub	 chains	
at	 Ser65,175,176	 which	 recruit	 Parkin	 to	 the	 OMM177	 and	 activate	
Parkin's	E3	Ub	ligase	activity	via	phosphorylation.178	Just	as	PINK1	
phosphorylates	 Ub,	 PINK1	 also	 phosphorylates	 Parkin	 directly	 at	
Ser65,179	 signifying	 a	 secondary	 mode	 of	 Parkin	 activation.180,181 
The	phosphorylated	Parkin	translocates	to	the	mitochondria	and	is	
further	activated	by	the	PINK1‐phosphorylated	Ub.177	Parkin's	sub‐
sequent	ubiquitination	of	OMM	substrates	leads	to	an	enrichment	of	
Ub	molecules	around	the	damaged	mitochondria	that	enter	a	posi‐
tive	feedback	cycle	through	PINK1	phosphorylation.182
PINK1	can	also	alter	OMM	signal	transduction	to	drive	fission.	
Activation	of	PINK1	destabilizes	the	interaction	between	PKA	and	
anchoring	 protein	 AKAP‐1,	 preventing	 unnecessary	 mitophagy.178 
The	 dissociation	 of	 PKA	 from	 AKAP‐1	 prevents	 phosphorylation	
and	 inhibition	 of	 Drp‐1	 leading	 to	 increased	 fission.	 Alternatively,	
PKA	 can	 translocate	 intracellularly	 and	 phosphorylates	 the	 mito‐
chondrial	membrane	protein	MIC60	on	Ser528,	preventing	PINK1	
accumulation	on	the	OMM	and	reducing	Parkin	recruitment	to	mi‐
tochondria.105	 In	 the	 presence	 of	mitochondrial	 pathology,	 PINK1	
likely	 drives	 reduced	mito‐PKA	and	AKAP,	 allowing	PINK1	 to	 flag	
the	 damaged	mitochondria	 for	 degradation	 through	 this	 feedback	
mechanism.
Accumulation	of	mitochondrial	mutations	is	observed	in	the	sub‐
stantia nigra	dopaminergic	(DA)	neurons	of	PD	patients	that,	due	to	
their	high	metabolic	needs,	may	result	 in	neuronal	death.	As	most	
mutations	associated	with	PINK1	are	in	the	kinase	domain,183,184	the	
adenosine	 triphosphate	 (ATP)	 analogy	 kinetin	 triphosphate	 (KTP)	
can	 be	 used	 to	 interact	 with	 PINK1,	 allowing	 for	 kinase	 activity	
and	Parkin‐induced	mitophagy	 independent	of	the	mutated	kinase	
domain.185	Huntington's	disease	 (HD)	 can	be	 characterized	by	 the	
presence	 of	 ring‐shaped	neuronal	mitochondria	which	 are	 formed	
in	 the	 presence	 of	 reduced	 mitophagy.186	 Overexpressing	 PINK1	
in	HD	models	reduces	the	formation	of	the	spheroid	mitochondria,	
decreases	the	number	of	damaged	mitochondrial,	and	counteracts	
neurotoxicity.187	 In	Alzheimer's	disease	(AD),	ectopic	expression	of	
PINK1	may	be	capable	of	reducing	or	even	preventing,	the	amyloid‐β 
(Aβ)	plaques	that	characterize	the	neurological	disease	as	an	accu‐
mulation	of	dysfunctional	mitochondria	and	oxidative	damage	have	
been	 shown	 to	 precede	 the	Aβ	 in	AD.188	 Thus,	 diminished	PINK1	
activity	could	be	a	basal	component	of	neurodegenerative	disease	
pathogeneses.
6  | OTHER KINASES ASSOCIATED WITH 
OMM
As	mentioned	earlier,	 the	occurrences	of	cytosolic	protein	kinases	
are	 increasing	 and	 more	 OMM	 kinases	 are	 being	 found	 through	
disease‐specific	 proteomic	 studies.	 These	 include	 protein	 kinases	
that	 are	 implicated	 in	 cellular	 homeostasis,	 such	 as	AMP‐depend‐
ent	protein	kinase	(AMPK),	casein	kinases	(CK1	and	CK2),	and	mam‐
malian	target	of	rapamycin	(mTOR).	 Intriguingly,	kinases	 implicated	
in	 the	cell	cycle	have	also	emerged	as	OMM	signaling	agents.	The	
appearance	of	these	kinases	on	the	OMM	is	further	evidence	of	the	
extensive	integration	of	organelle	and	cell	physiologies	and	quality	
control.
6.1 | AMP‐dependent protein kinase (AMPK)
A	 recent	 addition	 to	 the	 OMM	 signaling	 landscape	 is	 the	 AMP‐
dependent	 protein	 kinase	 (AMPK),	 which	 was	 identified	 in	 two	
independent	 reports.120,189	 First,	 Toyama	 and	 colleagues	 189 dem‐
onstrated	 that	 AMPK's	 response	 to	 ETC	 stress	 (rotenone	 or	 anti‐
mycin	 treatment)	 leads	 to	 the	 activation	 of	 AMPK	 and	 ultimately	
the	colocalization	with	TOMM20.	This	study	also	revealed	that	mi‐
tochondrial	 fission	 factor	 (MFF)	was	phosphorylated	by	AMPK	on	
Ser172,	which	was	required	along	with	Ser155	phosphorylation	for	
the	 recruitment	 of	 Drp1	 and	 ultimately	 stress‐induced	 mitochon‐
drial	fragmentation.189	Moreover,	phosphorylation	of	Mff	on	Ser172	
and	Ser155	was	found	to	be	essential	to	the	proper	distribution	of	
dendritic	mitochondria	 in	mouse	 primary	 cortical	 neurons.189	 This	
study	was	 important	because	 it	placed	AMPK	 in	proximity	 to	ATP	
production	and	provided	a	mechanistic	link	between	mitochondrial	
bioenergetics	and	dynamics.
Alternatively,	Hoffman	et	al120	utilized	phosphoproteomics	to	
identify	substrates	of	AMPK	in	continuous	cell	cultures	and	mus‐
cles.	One	 of	 the	 validated	 substrates	was	 an	OMM	 scaffold	 for	
PKA,	AKAP‐1.	AMPK	phosphorylation	of	AKAP‐1	on	Ser103	leads	
to	 increased	 respiration	 in	 rat	 L6	myoblasts	 likely	 in	 a	 PKA‐de‐
pendent	manner.120	As	mentioned	earlier,	enhanced	mitochondrial	
PKA	activity	is	linked	to	the	improved	import	of	ETC	components	
and	phosphorylation	of	ETC	enzymes	by	PKA	 improves	 activity.	
Therefore,	 AMPK	 activity	 on	 the	 OMM	 is	 a	 means	 to	 facilitate	
ETC	activity	by	 sustaining	PKA	activity	 through	manipulation	of	
the	 scaffold	 AKAP‐1.	 These	 studies	 demonstrate	 that	 AMPK	 is	
an	essential	 integrator	of	bioenergetic	status190,191	and	organelle	
dynamics192	on	the	mitochondrial	surface,	and	AMPK	activity	on	
mitochondria	may	be	a	player	in	CNS	disorders	such	as	PD193and 
ALS.194
6.2 | Cyclin‐dependent kinase 1 (Cdk1)
Cyclin‐dependent	 kinase	 1	 (Cdk1)	 complexed	 with	 cyclin	 B	 is	
known	 to	 impact	 mitochondrial	 substrates	 during	 mitosis.	 Cdk1	
was	first	reported	to	impact	mitochondrial	proteins	in	2007	when	
Taguchi	and	colleagues	discovered	that	Cdk1/cyclin	B	could	phos‐
phorylate	Drp‐1	on	Ser585	(Ser616	human)	and	promoting	mito‐
chondrial	fission	prior	to	cell	division.195	It	was	later	demonstrated	
that	Cdk1/cyclin	B	could	impact	matrix	proteins	as	well	including	
components	of	respiratory	complex	I.	The	phospho‐manipulation	
of	the	complex	I	subunits	ultimately	promoted	the	respiration	nec‐
essary	 to	 produce	 the	 bioenergetic	 currency	 necessary	 for	 cell	
division.196	Both	 the	 regulation	of	mitochondrial	 fission	and	 res‐
piratory	chain	by	Cdk1/cyclin	B	have	been	linked	to	oncogenesis	
and	therapeutic	resistance	in	brain	tumors	as	well	as	other	types	
848  |     LUCERO Et aL.
of	cancer.197	Collectively,	mitochondrial	 signaling	by	Cdk1/cyclin	
B	is	an	excellent	example	of	the	extensive	coordination	between	
mitochondrial	and	cellular	programming.
6.3 | Cyclin‐dependent kinase 5 (Cdk5)
Another	example	of	a	Cdk	exhibiting	OMM	signaling	capabilities	
is	 cyclin‐dependent	 kinase	 5	 (Cdk5).	 Like	Cdk1,	 Cdk5	 can	 phos‐
phorylate	Drp1	 on	 Ser616	 in	mature	 rat	 neurons,	 the	 same	 site	
as	Cdk1	 in	mitotic	cells,	 inhibiting	mitochondrial	 fission.198	Cdk5	
activity	 was	 associated	with	 elongated	mitochondria	 during	 the	
maturation	of	cultured	cortical	neurons.198	Intriguingly,	Cdk5‐me‐
diated	phosphorylation	of	Drp1	is	linked	to	oncogenic	potential	in	
brain	tumor	 initiating	cells,	 in	which	enhanced	Drp1	activity	cor‐
related	with	 a	 poor	 glioblastoma	 prognosis.199	 In	 another	 study,	
Cdk5	was	crucial	to	N‐methyl‐D‐aspartate	(NMDA)‐induced	neu‐
ron	loss,	and	elimination	of	Drp1	phosphorylation	or	the	catalytic	
activity	 of	 Cdk5	 was	 sufficient	 to	 prevent	 NMDA‐induced	 cell	
death.200	Furthermore,	cerebral	granule	cells	derived	from	Cdk5‐/‐ 
mice	were	 resistant	 to	NMDA‐induced	cytotoxicity	compared	 to	
controls.200	Cdk5	phosphorylation	of	Drp1	also	occurs	in	models	
of	neurodegenerative	disorders.	Cdk5‐mediated	phosphorylation	
of	Drp1	can	promote	fission	and	apoptosis	in	striatal	neurons	that	
express	mutant	Huntington,	an	event	that	can	be	exacerbated	by	
the	addition	of	dopamine.201	This	study	implicates	Cdk5‐Drp1	ac‐
tivation	as	a	component	of	Huntington	disease.	Additionally,	Cdk5	
phosphorylation	of	Drp1	occurs	in	mouse	primary	cortical	neurons	
exposed	to	amyloid	beta	 (Aβ1‐42).
202	Neurons	treated	with	Aβ1‐42	
exhibited	increased	fission	and	apoptosis	that	could	be	ablated	by	
impairing	Cdk5,	which	may	indicate	that	Cdk5	activation	of	Drp1	
may	be	involved	in	AD	pathophysiology.202	Intriguingly,	these	re‐
ports	place	a	cell	cycle	enzyme	in	stress	response	pathways	within	
postmitotic	cells.
6.4 | Cyclin‐dependent kinase 11 (Cdk11)
Similar	 to	 Cdk5,	 cyclin‐dependent	 kinase	 11	 (Cdk11)	 has	 been	
shown	 by	 colocalization	 studies	 to	 have	 subpopulation	 on	 mito‐
chondria.203,204	 After	 the	 identification	 of	 Cdk11	 on	 mitochon‐
dria,	 there	have	been	no	 follow‐up	studies	 to	 identify	 substrates.	
Intriguing	the	localization	of	Cdk11	preceded	the	induction	of	ap‐
optosis	leading	investigators	to	surmise	that	Cdk11	may	have	a	role	
in	the	induction	of	cell	death.203,204	Cdk11	represents	an	interesting	
OMM	kinase	for	study,	as	research	related	to	mitochondria.	Cdk11	
could	shed	light	on	the	relationship	between	organelle	physiology	
and	the	cell	cycle.
6.5 | Casein kinase I (CK1)
Both	casein	kinase	 I	and	 II	 (CK1	and	CK2)	have	been	described	to	
have	 mitochondrial	 influence	 and	 localization.124,205,206	 CK1	 and	
CK2	are	commonly	viewed	as	Ser/Thr	kinases	that	influence	the	ac‐
tivity	of	 transcription	 factors	 to	 influence	developmental	 signaling	
(ie,	Wnt	 pathway)	 and	 circadian	 rhythms.	However,	CK1	 and	CK2	
have	 been	 implicated	 in	 the	 regulation	 of	mitochondrial	 function.	
CK1	is	involved	the	inhibition	of	Fas‐mediated	apoptosis	through	the	
phosphorylation	of	Bid	on	Ser64	and	Ser66.207,208	Phosphorylation	
by	CK1	prevents	 the	cleavage	of	Bid	by	caspase	8	 limiting	 the	 re‐
lease	of	cytochrome	c	from	mitochondria.207,208	While	specific	CK1	
targets	 on	mitochondria	 have	 yet	 to	 be	 identified,	 CK1	 has	 been	
colocalized	with	mitochondria,	and	further	studies	may	unearth	CK1	
substrates	on	mitochondria.
6.6 | Casein kinase II (CK2)
The	 role	 of	 CK2	 on	 mitochondria	 is	 more	 extensive	 than	 CK1	
where	 in	 addition	 to	 apoptosis	 CK2	 plays	 a	 significant	 role	 in	
the	regulation	of	organelle	protein	 import122,123	and	quality	con‐
trol.206	 Concerning	 apoptosis,	 CK2	 is	 known	 to	 phosphorylate	
Bcl‐2	 proteins	 and	 affect	 their	 activities.	 An	 example	 includes,	
like	CK1,	CK2	can	phosphorylate	Bid	preventing	the	induction	of	
apoptosis,	activation	of	caspases,	and	sustaining	the	 levels	mito‐
chondrial	 Bcl‐2.207	 Recent	 data	 suggest	 CK2	 has	 a	more	 promi‐
nent	 role	 in	 the	 regulation	of	mitochondrial	protein	 import.	CK2	
has	 been	 associated	 with	 the	 phosphorylation	 of	 OMM	 protein	
transport	 components	TOM22	and	TOM70.122‐125	 In	both	cases,	
CK2	 enhances	 the	 localization	 and	 function	 of	 these	 transport	
proteins	 in	 the	OMM	and	 thus	positively	 impacts	protein	 transit	
into	 mitochondria.	 Additionally,	 CK2	 phosphorylation	 of	 Mim1	
complex	stabilizes	the	protein	in	the	OMM	and	leads	to	increased	
activity	including	the	incorporation	of	TOM22	into	the	OMM	and	
TOM	 super‐complex.122‐125	 CK2	 is	 implicated	 in	 mitophagy	 as	
well.206,209,210	CK2	phosphorylation	of	OMM	mitophagy	receptor	
FUN14	domain	containing	1	 (FUNDC1)211	on	Ser13	prevents	the	
interaction	of	mitochondria	with	LC3	reducing	mitophagy	perhaps	
as	a	means	to	retain	healthy	mitochondria.210	Therefore,	CK2	has	
emerged	as	a	crucial	element	of	mitochondrial	physiology	and	de‐
fects	in	CK2	function	could	adversely	affect	organelle	physiology	
and	related	human	conditions.
6.7 | Mammalian target of rapamycin (mTOR)
The	mTOR	signaling	pathway	has	long	been	implicated	in	sensing	mi‐
tochondrial	substrates	like	branched	amino	acids;	moreover,	mTOR	
has	been	linked	to	bioenergetics	and	mitochondrial	protein	synthesis	
for	some	time.212,213	The	localization	of	mTOR	signaling	components	
on	 lysosomes	 and	 in	 proximity	 to	 mitochondrial‐associated	mem‐
branes	(MAMs)	meant	it	was	only	a	matter	of	time	before	mitochon‐
drial	mTOR	substrates	would	be	discovered.214	 Indeed,	mTOR	was	
reported	to	localize	to	mitochondria	via	the	OMM	protein	FKBP38,	
a	member	of	the	FK506‐binding	protein	family.215	This	 interaction	
places	mTOR	in	close	to	Bcl‐2	proteins	associated	with	VDAC1.213,216 
Bcl‐2	proteins	associated	with	VDAC1	influence	substrate	entry	into	
mitochondria	and	dictate	the	cellular	reliance	on	glycolysis.	A	recent	
report	 demonstrates	 that	mitochondrial	mTOR	 can	 phosphorylate	
Bcl‐xL	on	Ser62	and	this	increased	cellular	reliance	on	glycolysis	in	
     |  849LUCERO Et aL.
leukemia	cells.213	The	 localization	of	mTOR	places	 the	kinase	near	
other	regulators	including	AMPK	making	mTOR	an	emerging	regula‐
tor	 of	mitochondria	 function	 capable	 of	 responding	 to	 changes	 in	
redox	status	and	bioenergetics	shifts.	Alternatively,	mTOR	may	have	
a	 role	 in	OMM	 signaling	 through	 interplay	with	 AKAP‐1,	wherein	
mitochondrial	 PKA	 signaling	may	 influence	mTOR	 activity.217	 It	 is	
clear	 that	 mTOR	 signaling	 is	 highly	 integrated	 with	 mitochondria	
physiology.212,218,219
6.8 | P21‐activated kinase 5 (PAK5)
The	p21‐activated	kinase	5	(PAK5)	 is	a	Ser/Thr	protein	kinase	that	
primarily	 regulates	 cytoskeleton	 dynamics	 and	 contributes	 to	 cell	
proliferation.220	 PAK5	 exhibits	 Rho‐kinase‐dependent	 mitochon‐
drial	 localization.221,222	 PAK5	 was	 shown	 to	 phosphorylate	 Bad	
on	Ser112	and	prevent	Bad	migration	 to	mitochondria.223	This	 in‐
creases	 levels	 of	Bcl‐2	 and	prevents	 apoptosis.223	 Further	 investi‐
gation	is	warranted	to	determine	whether	PAK5	can	phosphorylate	
other	BH3‐only	proteins	and	whether	these	modifications	coincide	
with	changes	in	cytoskeletal	dynamics.
The	number	of	reported	protein	kinases	localizing	to	mitochon‐
dria	 continues	 to	 grow	 at	 an	 increasing	 pace.	 The	 reports	 of	 new	
signaling	kinases	on	the	OMM	reflect	the	structural	and	functional	
integration	 of	mitochondria	 with	 other	 subcellular	 compartments.	
Thus,	the	kinases	presented	above	may	only	be	a	modest	sampling	
of	the	cascades	present	on	the	mitochondrial	surface.
7  | OMM PROTEIN PHOSPHATASES
Compared	 to	 the	breadth	of	 studies	on	OMM	protein	kinases,	 far	
less	is	known	regarding	the	activities	and	substrates	of	protein	phos‐
phatases	 on	 the	mitochondrial	 surface.	 Because	 a	 number	 of	 the	
phosphorylation	 events	 ascribed	 to	 protein	 kinases	 on	 the	 OMM	
are	reversible,	it	is	likely	that	some	phosphatases	would	be	required	
to	offset	and	regulation	these	phosphorylation	events	to	adjust	and	
maintain	 organelle	 physiology.8,11	We	will	 describe	 the	 actions	 of	
some	of	the	known	protein	phosphatases	on	mitochondria	below.
7.1 | Mitogen‐activated protein kinase 
phosphatase‐1 (MKP‐1)
MKP‐1	 is	 a	dual	 specificity	phosphatase	capable	of	dephospho‐
rylating	Ser/Thr	and	Tyr	residues	modified	by	protein	kinases.224 
As	 the	 name	 implies,	 the	 primary	 substrates	 of	MKP‐1	 are	 the	
MAPKs.	As	described	earlier,	MAPKs	(namely	JNK,	ERK1/2,	and	
p38)	 can	 translocate	 to	mitochondria	 and	manipulate	 local	 pro‐
teins.	MKP‐1	was	also	found	to	migrate	to	neuronal	mitochondria	
in	 response	 to	 treatment	 of	 cells	 with	 neuronal	 growth	 fac‐
tor.224,225	It	is	proposed	that	JNK	is	a	substrate	of	MKP‐1	on	mi‐
tochondria	based	on	brain‐related	studies	226‐228	suggesting	that	
MKP‐1	may	act	to	inactivation	JNK	signaling	to	prevent	apopto‐
sis.	Further	investigation	is	warranted	to	determine	whether	the	
phosphatase	affects	other	MAPKs	on	mitochondria	or	has	unique	
substrates	on	the	OMM.
7.2 | Phosphate and tensin homolog‐long (PTEN‐L)
A	recent	report	by	Wang	et	al	introduced	the	presence	of	the	long	
PTEN	 isoform,	 PTEN‐L,	 on	 the	 OMM.229	 Ectopic	 expression	 of	
PTEN‐L	impaired	mitophagy	by	preventing	Parkin	translocation	and	
reducing	the	levels	of	phosphorylated	ubiquitin	on	the	mitochondrial	
surface.	Ablation	of	PTEN‐L	expression	promoted	mitophagy	 sug‐
gesting	that	PTEN‐L	could	be	a	negative	regulator	of	PINK1‐depend‐
ent	mitophagy.229	 Intriguingly,	 site‐directed	mutagenesis	 to	 impair	
the	 lipid	phosphatase	activity	of	PTEN‐L	did	not	 impact	 its	 role	 in	
the	control	of	mitophagy.229	This	study	indicates	that	PTEN‐L	has	a	
unique	conformation	 that	permits	protein	phosphatase	activity	on	
the	OMM.
7.3 | Protein phosphatase 1 (PP1)
The	PP1	is	linked	to	the	regulation	of	local	signaling	transduction	on	
the	OMM	and	the	function	of	proteins	related	to	apoptosis.230‐233 
PP1	forms	a	complex	with	PKA	and	AKAP1	on	the	mitochondrial	
surface,234	and	in	the	absence	of	PKA,	PP1	can	destabilize	AKAP1	
leading	to	its	degradation	and	reduce	potential	sites	for	mitochon‐
drial	PKA	signaling.235	 This	event	was	 linked	 to	 the	 induction	of	
long‐term	depression	through	the	dephosphorylation	of	AMPA	re‐
ceptor.234	OMM	PP1	has	been	cited	as	a	regulator	of	p38	signaling	
on	mitochondria	as	well.	PKC	was	found	to	induce	PP1	following	
exposure	 to	 phorbol	 ester	 leading	 to	 dephosphorylation	 and	 in‐
activation	of	p38	on	the	mitochondria.231	These	studies	 indicate	
that	PP1	could	modulate	OMM	signaling	 in	a	context‐dependent	
fashion.
PP1	 is	 associated	 with	 the	 dephosphorylation	 of	 Bcl‐2	 proteins	
and	the	induction	of	apoptosis.232	PP1	dephosphorylation	of	Bad	can	
release	 the	 protein	 from	 14‐3‐3	 and	 permits	 Bad's	 interaction	with	
and	inhibition	of	anti‐apoptotic	Bcl‐2	proteins.128	PP1	interaction	with	
Bcl‐2	and	Bcl‐xL	can	also	impact	phosphatase	activity.236	These	results	
indicate	PP1	on	the	OMM	is	a	regulator	of	apoptotic	proteins.
7.4 | Protein phosphatase 2A (PP2A)
Similar	to	PP1,	PP2A	has	been	shown	to	have	mitochondrial	locali‐
zation	 to	 the	OMM,	where	 it	 can	 influence	 the	 activities	 of	Bcl‐2	
proteins	 and	Bad	by	dephosphorylation.237,238	However,	 a	 distinc‐
tion	between	PP1	and	PP2A	substrates	appears	to	be	the	ability	of	
PP2A	to	dephosphorylate	Drp‐1	and	activate	the	protein.	PP2A	was	
shown	to	modify	Ser656,	the	same	residue	phosphorylated	by	PKA,	
and	undo	PKA‐mediated	inhibition	of	Drp‐1	leading	to	mitochondrial	
fragmentation	and	depolarization.95	In	neurons,	PP2A	activation	of	
Drp‐1	led	to	decrease	synapse	formation	and	shorter	and	fewer	den‐
drites.95	 Excessive	PP2A	activity	 could	be	a	player	 in	neurological	
conditions	that	may	have	fragmented	mitochondrial	networks,	such	
as PD.
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7.5 | Protein tyrosine phosphatase, non‐receptor 
type 11 (PTP1D)
PTP1D	is	another	phosphatase	that	has	been	associated	with	AKAP1	
on	the	OMM.239	PTP1D	in	response	to	EGF	signaling	can	dephos‐
phorylate	Src	activating	its	kinase	activity.	Increased	Src	activity	is	
associated	with	increased	ETC	activity	by	direct	phosphorylation	of	
subunits	by	Src.239	In	such,	PTP1D	may	act	to	supplement	PKA	sign‐
aling	through	a	shared	molecular	interaction	with	AKAP1.
Given	 the	 diversity	 of	 signaling	 molecules	 present	 on	 the	 mi‐
tochondrial	 surface	 and	 the	 multitude	 of	 physical	 and	 functional	
interfaces	of	the	OMM,	it	is	likely	that	the	number	of	protein	phos‐
phatases	will	increase	to	regulate	the	growing	populations	of	protein	
kinases	on	the	cell	surface.	Further	 investigation	 into	the	dynamic	
assembly	 and	disassembly	of	OMM	signaling	 cascades	may	 reveal	
the	identity	of	new	OMM	phosphatases	or	new	substrates	for	exist‐
ing	OMM	phosphatases.
8  | OMM SCAFFOLD PROTEINS
Scaffold	 proteins	 and	 adaptor	 proteins	 are	 crucial	 accessory	 pro‐
teins	 required	 for	 the	 coordination	 of	 signal	 transduction	 events	
across	 space	 and	 time.240,241	The	 relative	 abundance	of	 accessory	
proteins	can	dictate	the	biological	outcomes	of	signaling	events	by	
influencing	the	spatial	magnitude	and	duration	of	a	response.240,241 
Therefore,	the	identification	and	concentrations	of	these	elements	
of	molecular	architecture	will	be	critical	to	determine	the	presence	
and	impact	of	signaling	pathways	on	mitochondria.
8.1 | A‐kinase anchoring protein 1 (AKAP‐1)
AKAPs	are	membrane‐bound	scaffolds	for	PKA	and	its	related	sign‐
aling	components.91	AKAP‐1	can	exhibit	mitochondrial	 localization	
(often	referred	to	as	D‐AKAP1),	and	reports	have	placed	it	on	and	
within	mitochondria.242	Of	note,	 the	mitochondrial	variants	of	 the	
Akap1	 gene	most	 often	 associated	with	 the	OMM	are	 sAKAP‐84,	
AKAP‐121,	 and	 AKAP‐149.242	 Single	 nucleotide	 polymorphisms	 in	
Akap1	can	alter	the	subcellular	distribution	of	AKAP1	variants	and	
alter	the	outcomes	of	cAMP/PKA	signaling.243	 Indeed,	the	relative	
levels	of	AKAP1	on	the	mitochondria	can	influence	the	outcomes	of	
local	PKA	signaling.95,96,244‐247	By	merely	increasing	AKAP‐1	concen‐
trations	on	mitochondria,	 investigators	have	been	able	to	 leverage	
the	prominent	concentrations	of	PKA	in	the	cytosol	to	influence	mi‐
tochondrial	health.	Overexpression	of	AKAP‐1	can	protect	neurons	
and	 neuron‐like	 cells	 against	 PD	 relevant	 neurotoxins	 and	 PINK1	
deficiency	as	noted	earlier.	Furthermore,	genetic	ablation	of	AKAP1	
was	found	to	exacerbate	stroke‐related	injury	in	mice.100	The	dele‐
tion	of	Akap1	in	mice	reduced	phosphorylation	of	Drp‐1	on	Ser637,	
which	impaired	fission.100	Reduced	Drp1	phosphorylation	in	Akap1‐/‐ 
mice	contributed	to	Ca2+	dysregulation,	dysregulation	of	complex	II,	
and	increased	ROS	production	in	response	to	excitotoxic	stress.100 
This	suggests	that	the	PKA/AKAP1	mitochondrial	signaling	nexus	is	
crucial	to	regulating	stress	responses	and	preserving	optimal	orga‐
nelle	function	in	the	brain.
A	 recent	 report	 indicates	 that	 mitochondria	 AKAPs	 are	 ar‐
ranged	 into	 specialized	membrane	microdomains	and	 this	physical	
interaction	 places	 PKA	 proximal	 to	mitochondrial	 substrates	 such	
as	 Bad.248	 These	microdomain	 associations	 are	 greatly	 influenced	
by	 local	 phosphatases	 capable	 of	 influencing	 the	 stability	 of	 PKA	
signaling	on	the	OMM.	Recently,	post‐translational	modification	of	
AKAP‐1	has	been	shown	to	affect	protein	stability	on	the	OMM	as	
well.	 Dephosphorylation	 of	 AKAP‐1	 can	 lead	 to	 its	 ubiquitination	
by	 E3‐ubiquitin	 ligase	 seven	 in	 absentia	 2	 (Siah2)	 resulting	 in	 its	
degradation.244	 This	 ultimately	 diminishes	 PKA	 concentrations	 on	
mitochondria,	which	can	impair	the	beneficial	effects	of	 local	PKA	
signaling.244	Given	 the	 anomalies	 related	 to	PKA	 signaling	 in	neu‐
rodegenerative	disorders,	 it	 is	 likely	 that	disorientation	and	desta‐
bilization	of	AKAP‐1	on	the	OMM	could	be	responsible	for	the	lack	
of	mitochondrial	health	in	conditions	such	as	AD	and	PD.	Restoring	
optimal	levels	of	mitochondrial	PKA	signaling	could	help	restore	or‐
ganelle	function	and	reduce	the	detrimental	effects	of	mitochondrial	
perturbations	in	neurodegenerative	disease.
8.2 | Sab (SH3‐binding protein 5; SH3BP5)
As	mentioned	above,	Sab	is	an	OMM	scaffold	for	the	JNK	and	a	pu‐
tative	substrate	of	p38γ	on	the	OMM.27,28	To	date,	no	other	outer	
membrane	 kinases	 have	 been	 shown	 to	 interact	 with	 Sab.	 This	
could	be	due	 to	 the	 topology	of	Sab,	which	may	make	 it	 selective	
for	MAPKs	 on	 the	 OMM.	 Near	 the	 C	 terminus	 of	 Sab,	 there	 are	
two	kinase	 interacting	motifs	 (KIM1	and	KIM2)	 (see	Figure	2).	The	
Sab	KIM1	motif	is	immediately	followed	by	a	transmembrane	motif,	
which	would	indicate	that	KIM2	is	the	only	kinase	interacting	motif	
on	the	cytosolic	side	of	the	OMM.	Previous	studies	have	indicated	
that	JNK	interacts	with	Sab	through	the	KIM1	motif,	while	the	KIM2	
motif	 was	 dispensable	 for	 JNK‐mediated	 phosphorylation.29,55	 A	
study	by	Win	et	 al29	 demonstrating	 the	 topology	of	Sab	 indicates	
that	JNK	is	on	the	cytosolic	face	of	the	OMM	and	likely	interacting	
with	KIM2	of	Sab.	A	recent	study	from	our	laboratory	indicates	that	
JNK	phosphorylates	Sab	on	Ser421	which	 is	near	KIM2	 indicating	
that	KIM2	is	likely	the	binding	site	for	JNK	on	the	OMM.32	Selective	
inhibition	of	 the	JNK‐Sab	 interaction	 reveals	 that	KIMs	are	neces‐
sary	 for	 JNK	signaling	on	 the	mitochondria	and	 JNK‐related	mito‐
chondrial	activities.26,31‐33,54,249,250	The	concentrations	of	Sab	on	the	
OMM	dictate	the	outcomes	of	mitochondrial	JNK	signaling.31,32,250 
Recent	studies	from	our	laboratory	demonstrate	that	increasing	Sab	
levels	 in	mitochondria	 renders	 cells	 vulnerable	 to	 stresses	 due	 to	
elevated	 levels	of	JNK	signaling	on	the	OMM.	Demonstrating	that	
the	relative	levels	on	scaffold	proteins	on	the	OMM	dictate	signaling	
outcomes,	and	the	collective	levels	of	distinct	scaffolds	could	indi‐
cate	how	mitochondria	may	 respond	 to	cellular	cues	and	stresses.	
We	have	found	that	Sab	mRNA	and	protein	 levels	are	significantly	
enriched	 in	 the	 hippocampus,	 substantia	 nigra,	 and	 cerebellum,	
areas	 of	 the	 brain	 vulnerable	 to	 neurotoxin	 stimuli.251	 Thus,	 we	
contend	that	the	elevated	Sab	concentrations	could	lead	to	robust	
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mitochondrial	JNK	activity	contributing	to	apoptosis	and	neurode‐
generation	in	disorders	such	as	AD	and	PD.	Selective	disruption	of	
the	JNK‐Sab	interaction	protects	dopaminergic	neurons	from	6‐hy‐
droxydopamine‐induced	 neurotoxicity.33	 Thus,	 the	 specific	 target‐
ing	of	detrimental	mitochondrial	JNK	signaling	could	be	a	promising	
target	to	preserve	mitochondrial	health	in	PD.
8.3 | Protein interacting with C‐kinase‐1 (PICK1)
PICK1	 is	 a	 scaffold	 protein	 for	 PKCs,	 and	 PICK1	 has	 been	 linked	
to	PKAα	 localization	on	mitochondria,	where	the	kinase	protected	
against	apoptosis	induced	by	genotoxic	stress.252‐254	Another	report	
indicates	that	PICK1	on	mitochondria	can	impair	Parkin	activity	and	
contribute	 to	MPTP‐induced	neurotoxicity.	PICK1	destabilized	 the	
interaction	 between	 Parkin	 and	 UbcH7	 leading	 to	 diminished	 E3	
ubiquitin	 ligase	activity	of	Parkin.	PICK1	knockout	mice	were	pro‐
tected	against	MPTP‐induced	cell	death.255	This	effect	of	PICK1	is	
interesting	in	light	of	the	neurotoxic	and	neuroinflammatory	activi‐
ties	of	PKCδ	and	may	be	another	mechanism	by	which	shifts	in	OMM	
signaling	can	contribute	to	PD	pathogenesis	and	progression.256
Additional	scaffold	proteins	may	also	be	localized	to	the	OMM,	as	
reports	indicate	that	14‐3‐3	may	have	a	population	of	mitochondrial	
proteins	 that	 influence	 organelle	 signaling.257,258	 Also,	 the	 growth	
factor	receptor‐bound	protein	10	(Grb10)	may	have	OMM	localiza‐
tion.259	We	contend	that	the	accurate	and	reliable	identification	of	
OMM	scaffold	proteins	will	be	crucial	to	determining	the	localization	
and	signaling	pathways	to	the	mitochondrial	surface.
9  | CONCLUDING REMARKS AND FUTURE 
DIRECTIONS
In	 this	 review,	we	have	presented	 some	of	 the	emerging	 signaling	
cascades	and	phosphorylation	events	on	the	mitochondria	surface.	
OMM	signaling	components	are	appropriately	positioned	to	impact	
specific	aspects	of	mitochondrial	physiology.	It	is	likely	that	more	rig‐
orous	studies	in	this	area	will	unearth	more	kinases,	phosphatases,	
and	adaptor	proteins.	Great	 care	 should	be	 taken	 in	 identification	
and	validation	of	new	signaling	components	on	the	OMM	using	es‐
tablished	as	well	as	modern	proteomic‐based	approaches.
While	 the	 identification	 of	 OMM	 signaling	 components	 and	
signaling	cascades	continues	 to	be	of	 interest,	many	of	 the	OMM	
kinases	are	beginning	to	demonstrate	interplay	on	the	organelle	sur‐
face.	Earlier,	we	mentioned	that	AMPK	could	stabilize	PKA	signaling	
on	mitochondria	to	enhance	ETC	function.120	However,	antagonism	
by	kinases	may	also	occur.	The	best	current	evidence	for	this	is	that	
PINK1	 can	 impair	 the	 kinase	 activity	 of	 LRRK2,260‐262	 an	 effect	
which	 is	 lost	 in	 iPSC‐derived	neurons	 from	PD	patients	harboring	
PINK1	mutations.	 Similarly,	 overexpression	 of	 Parkin	 can	 prevent	
dopaminergic	neuron	loss	in	the	presence	of	LRRK2:G2019S.260,261 
In	 addition	 to	 modulating	 protein	 function,	 it	 is	 likely	 that	 sig‐
naling	 cascades	 can	 target	 opposing	 pathways	 for	 degradation	
using	by	manipulating	 local	 E3‐ubiquitin	 ligases	or	other	 turnover	
mechanisms	 (ie,	autophagy).	But,	one	can	anticipate	that	the	scaf‐
folding	and	organization	of	 these	molecular	pathways	will	be	crit‐
ical	to	this	integration.	This	potential	has	been	noted	with	AKAP1,	
which	plays	a	crucial	role	in	the	integration	of	PKA	and	mTOR	sig‐
naling	modules.217	It	is	likely	that	similar	mechanisms	exist	for	other	
signaling	proteins	to	balance	mitochondrial	form	and	function	in	an	
everchanging	cellular	environment.	Research	oriented	around	these	
distinct	 interactions	will	 be	 critical	 to	 understanding	 the	 complex	
regulation	 of	 mitochondrial	 function	 and	 dysfunction	 in	 disease	
pathogenesis,	and	this	scenario	also	highlights	the	need	to	consider	
therapeutic	regimens	that	impair	detrimental	events	while	restoring	
beneficial	signaling	pathways	on	the	OMM.
It	 is	 likely	 that	 the	OMM	signaling	pathways	will	be	highly	 re‐
sponsive	 to	 mitochondrial	 messengers,	 such	 as	 ROS,	 and	 OMM	
proteins	 are	 appropriately	 positioned	 to	 recognize	 and	 response	
to	 these	 small	molecules.	 The	 response	 to	 these	messengers	will	
shape	cellular	 responses	 to	the	organelle	health	status.	An	exam‐
ple	of	this	type	of	integration	may	be	best	illustrated	by	the	inter‐
play	between	ROS	and	the	members	of	the	Bcl‐2	superfamily	that	
dictate	apoptotic	responses.263	For	example,	Bcl‐2	can	“sense”	the	
magnitude	 of	 ROS	 production	 in	 response	 to	 post‐translational	
modifications,	 namely	 Ser70	 phosphorylation,264	 and	 changes	 in	
Bcl‐2	 can	 then	 impact	 ETC	 function,	 mitochondrial	 antioxidant	
capacity,	 and	 autophagic	 flux.263	 The	 robustness	 of	 the	Bcl‐2	 re‐
sponse	 to	 ROS	 levels	 can	 determine	 whether	 a	 cell	 undergoes	
apoptosis.	 Our	 work	 demonstrates	 that	 enhancing	 mitochondrial	
JNK	 signaling	 by	 increasing	 Sab	 levels	 amplifies	 ROS	 production	
and	renders	cells	sensitive	to	chemical	insults	in	part	by	diminishing	
OMM	Bcl‐2	levels.31,32,250	It	is	established	that	mitochondrial	ROS	
can	 trigger	ASK‐1	 to	 engage	 sustained	 JNK	 activity265	 leading	 to	
depletion	of	OMM	Bcl‐2	by	Ser70	phosphorylation	and	induction	of	
apoptosis.26	In	addition	to	JNK,	numerous	OMM	localized	kinases	
and	phosphatases	can	modulate	Bcl‐2	superfamily	protein	function,	
which	we	contend	is	one	significant	route	to	coordinating	organelle	
and	cellular	physiology	because	of	the	importance	of	Bcl‐2	proteins	
to	metabolism,	autophagy,	and	apoptosis.	The	actions	of	OMM	sig‐
naling	proteins	in	response	to	ROS	could	dictate	the	actions	of	Bcl‐2	
proteins	within	the	cell.	Thus,	 it	 is	 imperative	that	OMM	signaling	
pathways	converging	on	Bcl‐2	proteins	be	considered	with	great	re‐
spect	toward	cellular	environment.
In	conclusion,	the	signalosomes	of	the	OMM	are	the	gatekeepers	
of	mitochondrial	physiology	and	mediators	of	disease	pathogenesis	
in	the	CNS,	as	such	there	is	much	promise	in	the	elucidation	of	sig‐
naling	relationships	on	the	mitochondrial	surface	and	targeting	dis‐
tinct	OMM	signaling	components	to	combat	CNS	disorders.
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